Check for updates

Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

Mohamed S. Nafie, [ID] *[ab] Ihab Shawish,[c] Sherif Ashraf Fahmy, [ID] *[d] Mohamed K. Diab, [ID][e] Mariam M. Abdelfattah,[f] Bassel M. Hassen,[f] Khaled M. Darwish, [ID][gh] Ayman El-Faham [ID][ij] and Assem Barakat [ID] *[k]

Halogenated spirooxindoles have garnered increasing attention as promising targeted anticancer therapy agents, owing to their improved binding affinity and ability to engage diverse molecular targets. These compounds demonstrate notable anticancer activity across various human malignancies, attributed to their selectivity targeting and reduced toxicity profiles. Functioning as multitarget agents, halogenated spirooxindoles exert biological effects through mechanisms including kinase inhibition, disruption of the MDM2–p53 interaction, DNA-binding modulation, and activation of apoptosis pathways. Their multifaceted activity profile supports their potential as next-generation anticancer agents, suggesting that further studies will be required in this direction. *Areas covered*: the recent developments of synthetic routes of derivatization and anticancer activities of halogenated spirooxindoles scaffolds during 2020–2025 are thoroughly covered. *Expert opinion*: halogenated spirooxindoles represent a strategic advance in the development of targeted cancer therapy, combining structural ingenuity with mechanistic precision. These findings encourage medicinal chemists to optimize further halogen placement, scaffold rigidity, and hybrid designs that could lead to new target-oriented chemotherapeutics.

Introduction

Cancer remains a leading cause of death in both developed and developing nations, with a global increase in burden expected due to population growth and aging demographics.[1] In 2020, an estimated 19.3 million new cancer cases and 10 million cancer-related deaths were reported worldwide, according to GLOBOCAN data.[2] Cancer is characterized by the abnormal growth of cells that typically proliferate uncontrollably. Meanwhile, the structural and functional heterogeneity of cancer cells makes it difficult to achieve high therapeutic selectivity.[3] Increasing knowledge in understanding the molecular changes that control the cell cycle and the uncontrolled growth of cancer cells provides valuable guidance for designing cancer-specific drugs.[4]

Spiro compounds have long held significance in organic synthesis due to their notable biological activities.[5] Specifically, spirooxindole derivatives have emerged as attractive synthetic targets, mainly due to their occurrence in numerous natural products and pharmacologically active molecules.[6] A defining structural feature of these compounds is the spiro-fused ring system at the C3 position of the oxindole core, which incorporates diverse heterocyclic motifs. Halogenated spirooxindoles, in particular, exhibit potent anticancer activity across multiple cancer types, owing to their ability to modulate a range of molecular targets.[7,8]

[a]*Department of Chemistry, College of Sciences, University of Sharjah, Sharjah (27272), United Arab Emirates. E-mail: mohamed.elsayed@sharjah.ac.ae; mohamed_nafie@science.suez.edu.eg*

[b]*Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia (41522), Egypt*

[c]*Department of Math and Sciences, College of Humanities and Sciences, Prince Sultan University, Riyadh 11586, Saudi Arabia*

[d]*Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert-Koch-Str. 4, Marburg, (35037), Germany. E-mail: sheriffahmy@aucegypt.edu*

[e]*Pest Physiology Department, Plant Protection Research Institute, Agricultural Research Center, Giza, (12311), Egypt*

[f]*College of Biotechnology, Misr University for Science and Technology (MUST), 6th of October City, Egypt*

[g]*Department of Medicinal Chemistry, Faculty of Pharmacy, Galala University, New Galala (P.O. 43713), Egypt*

[h]*Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia (P.O. 41522), Egypt*

[i]*Department of Basic Medical Sciences, College of Medicine, Dar Al Uloom University, P. O. Box 45142, Riyadh 11512, Saudi Arabia*

[j]*Department of Chemistry, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 21321, Egypt*

[k]*Department of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia. E-mail: ambarakat@ksu.edu.sa*

Halogenated spirooxindole alkaloids often exhibit marked biological activities strongly influenced by halogen substituents within their structures.[9] Spiro compounds remain a subject of interest in research into synthetic chemistry and, indeed, the focus of attention in the synthesis of naturally occurring compounds, where reaction conditions are often tailored to expand the scope of applicable transformations or to favor the formation of specific diastereomers.[10] In recent years, multi-component reactions, recognized as efficient strategies for constructing complex heterocyclic systems, have been increasingly employed in the synthesis of spiro compounds.[11]

Halogenated spirooxindoles have garnered increasing attention for their ability to effectively suppress the growth and proliferation of various cancer cell types.[12] Recent studies have indicated that the anticancer activities involve several pathways or processes *via* oxidative stress, autophagy, apoptosis induction,[13] caspase activation, cyclooxygenase-2 (COX-2) down-regulation, death receptor agonism and trafficking, mTOR pathway modulation and inhibition of survivin expression, designing and cellular anti-angiogenesis, p53 expression and activation,[14] reactive oxygen species (ROS) generation, sphingomyelinases modulation,[9] telomerase inhibition, topoisomerase I/IIα inhibition or tubulin interaction, mitochondrial membrane depolarization, mitochondrial respiratory chain complex.[15] Moreover, halogenated spirooxindoles have been reported to interfere with caspase inhibition, intracellular substance accumulation, and STAT activation in combination with them.[16] Their efficacy can be further enhanced through synergistic combinations, such as biphenyl carbamate arsenoxide and various organosilicon compounds, or by sensitizing cancer cells to tumor necrosis factor (TNF) cytokines, resulting in amplified antitumor effects.[17] In these signaling pathways and antitumor effects, kinase inhibition, including both mono-target and multi-target pathways, plays a key role in exploring therapeutic mechanisms.[8] Additionally, they have also shown some other effects of exerting their antitumor activity, such as HsPPIg-mediated suppression of pancreatic tumor growth by blocking paracrine signals within the tumor microenvironment.[18] ROS and human serum albumin (HAS), combined with a few, can react with DNA to induce depurination of the guanine base, leading to a further cytotoxic effect.[7]

Kinases represent a significant family of proteins attracting attention both as therapeutic targets and experimental tools.[19] Serine/threonine and tyrosine kinases can regulate a wide range of cellular functions, including growth, survival, and metabolism.[20] The oncogenic potential of kinases has been demonstrated in various clinical cases, like BCR-ABL in chronic myeloid leukemia and ABL in gastrointestinal stromal tumors.[21] Several studies have reported a direct correlation between enzymatic overexpression or mutational activation and cancer insurgence.[22] For instance, approximately 50% of casein kinase isoforms are overexpressed in lung medium adenocarcinoma, an event associated with early tumor progression.[23] Overexpression of cyclin-dependent kinase 2 (CDK2) was detected in 49% of invasive cancer cells in Asians, and it was demonstrated that the hepatocellular carcinoma with S/T somatic mutations chi-square equals 7.90.[24] Furthermore, a less regulated C-

terminus has been linked to the presence of Ala, whereas residues such as Glu, Asp, and Phe are related to protein delocalization.[25,26] Kinases involved in critical signaling pathways include glycogen synthase kinase 3, Janus kinase, Ca^{2+}-dependent protein kinase, Polo-like kinase, lipid kinase, casein kinase, cyclin-dependent kinases, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), protein kinase B (AKt), ERK, and PKC isoforms such as PKC-α, and PKC-δ.[27–31]

Over the past few decades, various kinase inhibitors have significantly impacted the clinical landscape, revolutionizing cancer treatments.[28] Several decades of drug approval have drastically improved the methodological development and advancements in kinase-targeted therapies.[32] Rational drug design and medicinal chemistry efforts, particularly in the later stages of the drug design process, have led to the discovery of several promising kinase-targeted drugs.[33,34] Drug discovery was reanalyzed to identify new strategies for enhancing the therapeutic efficacy of kinase inhibitors.[32] Most kinase inhibitors act as active site-directed, ATP-competitive inhibitors, and unfortunately, they are limited due to a lack of selectivity over other typical cellular kinases.[35] The focus of current drug development is to overcome the therapeutic limitations of first-generation kinase inhibitors.[36] The discovery of spirooxindole as a molecular core integrated into multikinase inhibitors has been extensively studied at the fundamental level, demonstrating both hit and lead compounds characterized by strong anticancer properties.[9,37] Specifically, halogenated spirooxindole has shown promising anticancer activity by targeting kinases involved in breast cancer.[18] Recent studies have demonstrated that halogenated spirooxindole derivatives target Polo-like kinase, cyclin-dependent kinase 2, phosphoinositide 3-kinase, and receptor tyrosine kinase families in breast cancer.[38] This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.[7] In conclusion, this research provides the first scientific evidence supporting the development and synthesis of spirooxindole-derived molecules for the selective targeting of anticancer kinases in breast cancer cells.[8]

In addition to their direct cytostatic activity, which remains to be fully elucidated, halogenated spirooxindoles appear to influence several other cellular pathways and processes, including apoptosis, cellular senescence, and autophagy.[14] They have been shown to promote increased oxidative stress within cancer cells, potentially releasing reactive oxygen accumulations to trigger cell cycle arrest.[13] Furthermore, it is feasible that halogenated spirooxindoles interact with the tumor microenvironment, possibly influencing immune modulation.[9] These multifaceted effects suggest that halogenated spirooxindoles possess a promising therapeutic potential extending beyond the traditional scope of kinase inhibitor research.[18]

Bioactivity of halogenated spirooxindoles as anticancer agents

In vitro studies have been conducted to determine the anticancer efficacy of halogenated spirooxindoles, comparing their cytotoxic and apoptotic effects to those of reference compounds

or adjuvant treatments on several cancer cell lines and normal cells.[39] These pharmacological studies specifically evaluate cell viability and/or cytotoxicity, apoptosis induction, cell cycle arrest, modulation of protein expression, the visualization and quantification of reactive oxygen species (ROS), and the impact on certain metabolic pathways.[18] Both halogenated and non-halogenated spirooxindoles have shown cytotoxic and apoptotic effects on different cell lines, including melanoma, hepatocarcinoma, pancreatic cancer, cervical cancer, prostate, acute promyelocytic leukemia, and adenocarcinoma.[12,37] They also demonstrated low cytotoxicity on normal fibroblasts and lymphocytes, while human fibroblasts showed particular sensitivity to their treatment.[17]

Based on the *in vitro* findings, some of these spirooxindoles were tested on xenografts in research organizations using animals certified for preclinical studies.[40] These studies aim to evaluate the animals' responses to new treatments in terms of observable outcomes and severity limits in order to calculate the dosage to be tested in humans.[41] Following promising results in the initial patient cohort, preclinical studies explored the combination of halogenated spirothiazolidinediones with established therapeutic drugs.[42] To end, mice belonging to the tumor histotype were treated with daily or weekly administrations of a specific dose of the drug. The treatment must be well tolerated by the animals.[43] Establishing the safe doses of new drugs or combinations of existing ones in animal models informs decisions that can avoid overdosing with consequent toxic effects or a dose that seems to be too low, as with certain substances.[44] However, these preclinical studies in animal cancer models are an important factor that demonstrates their effectiveness in living organisms and, therefore, can be tested in humans according to the protocol established during the research process.[45]

Several series of spirooxindoles have been utilized for the development of kinase inhibitors, especially for anticancer drug discovery.[7] These potent hinge-binding inhibitors exploit chemotherapy combined with pharmacological bypassing of alternative signaling pathways that are frequently enhanced in cancer.[18] The molecules identified in this review demonstrate excellent kinase activity, either *in vitro* or in cell potency, or at least *in silico*.[46] Some of them have displayed *in vivo* efficacy and selectivity.[40] Finally, some are currently under clinical trial studies.[41] Based on all these aspects, time-to-event studies should be performed, and the clinical trial results must be available, which will prove the efficacy of spirooxindole kinase inhibitors in cancer therapeutics.[47] Anticancer drugs are primarily discovered by focusing on the inhibitory activity of these molecules against specific cancer-associated kinases and other anticancer targets through docking studies of high-throughput screening hit molecules.[48,49] However, these methods have limitations due to the inaccurate protein kinase model, the non-valuable consideration of protein flexibility, and the neglect of conserved water molecules.[50] All these factors limit the success of the drug, which leads to current cancer treatment. A reliable and straightforward way to discover a potential drug is through tedious biological screenings.[51] At the same time, these challenges may also require chemical strategies, such as the synthesis of new small molecules. Consequently, several spirooxindole pharmacophores have been employed as selective, potent, and druggable kinase inhibitors.[38]

Mechanistic aspects of the halogenated spiro-oxindoles as anticancer agents

Due to their role in influencing key molecular pathways that advance cancer, halogenated spiro-oxindoles are considered viable anticancer therapeutics. These unique chemical substances showcase their capacity to suppress cell proliferation by utilizing different mechanisms, which involve inducing apoptosis, stopping the cell cycle, and activating ferroptosis, as clarified in (Fig. 1).[51]

One of the major anticancer mechanisms of halogenated spiro-oxindoles involves disrupting the p53–MDM2 interaction; the tumor suppressor protein p53 plays a pivotal role in regulating cell cycle arrest and apoptosis.[41] During normal physiological conditions, p53 performs negative modulation by MDM2, an E3 ubiquitin ligase that fosters the ubiquitination of p53, thereby resulting in its clearance through the proteasomal mechanism. Disruption of the p53–MDM2 interaction leads to stabilization and activation of p53, promoting apoptosis in cancer cells.[52] Additionally, these specific agents have been shown to assist in apoptosis by inhibiting BCL-2 expression and promoting caspase activation, thereby causing the release of mitochondrial cytochrome c and the initiation of programmed cell death.[53]

Cell cycle regulation is another crucial target of halogenated spiro-oxindoles. These specific compounds have demonstrated their potential to inhibit cyclin-dependent kinase 2 (CDK2), thereby preventing the transition from the G1 phase to the S phase and effectively halting cellular proliferation.[54] Furthermore, the inhibition of these compounds on histone deacetylase (HDAC) induces chromatin remodeling, suppressing oncogenic transcription and leading to cell cycle arrest.[16]

In addition to apoptosis, halogenated spiro-oxindoles have been implicated in inducing ferroptosis, an iron-dependent form of programmed cell death characterized by lipid peroxidation. Glutathione peroxidase 4 (GPX4) is a key enzyme that protects cells from lipid peroxidation, at which inhibiting GPX4 can induce ferroptosis, providing a novel approach to eliminating cancer cells. Although direct evidence of halogenated spiro-oxindoles targeting GPX4 is scarce, their potential to modulate oxidative stress pathways warrants further investigation.[55]

The ability of halogenated spiro-oxindoles to inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor (EGFR) is particularly significant in limiting tumor angiogenesis and metastasis. By blocking these receptors, the compounds reduce the availability of survival signals for cancer cells, thereby inhibiting the MAPK and PI3K/AKT signaling pathways that are frequently dysregulated in cancers, which promotes cell survival and proliferation. Targeting these pathways can enhance the efficacy of anticancer therapies.[56] The RAS/RAF/MEK/ERK (MAPK) and PI3K/AKT/

Fig. 1 The mechanistic pathways for the therapeutic potential of halogenated spirooxindoles as anti-cancer agents.[51]

mTOR signaling pathways are frequently dysregulated in cancers, promoting cell survival and proliferation.[57]

Specific studies on halogenated spiro-oxindoles targeting Cluster of Differentiation Receptor (CD44) and Human Epidermal Growth Factor Receptor 2 (HER-2) are less available. However, they are also known to contribute to cancer cell survival and metastasis by inhibiting the RAS/RAF/MEK/ERK (MAPK) and PI3K/AKT/mTOR signaling pathways, so inhibiting these pathways could potentially disrupt cancer progression and enhance treatment outcomes.[58,59]

Halogenated spiro-oxindoles function as dual inhibitors of Topoisomerase I and II by interfering with the enzymes' ability to cleave DNA strands, thus converting them into physiological poisons that induce DNA damage and trigger cell death.[60]

Molecular perspective of spirooxindole scaffold as a promising kinase inhibitor

Targeting several members of the kinase family has raised the adequacy of the spirooxindole scaffold to fulfill the structural requirements and molecular landscape of the kinase catalytic domain.[49] Comprising almost 300 amino acids, the overall folding and tertiary protein architecture of the kinase catalytic domain have been recognized as conserved across the kinase superfamily.[61] This canonical domain of the kinase enzymes comprises two lobes (N- and C-terminal lobes) linked through a flexible hinge region. The large C-lobe is of predominant α-helix architecture (six helices), while the smaller catalytic domain (N-lobe) comprises singular α-helix (αC-helix) and five β-sheets (Fig. 2A). Kinase ATP-substrate binding site is typically a hydrophobic shallow surface groove being made by the residues of both structural lobes.[62,63] This catalytic ATP-binding hydrophobic cleft is druggable for several small hydrophobic molecules and harbors the key structural motifs responsible for target activation.[64]

Topological and structural analysis of the kinase catalytic site highlighted the following subregions for kinase inhibitor binding: a solvent-exposed hydrophobic region, adenine-specific pocket, bridge portion linker site, and deep buried hydrophobic region (Fig. 2B).[65,66] The adenine-specific pocket is settled at the center of the catalytic site where inhibitors

Fig. 2 Architecture of kinase's catalytic domain and molecular aspects of spirooxindole scaffold binding at the ATP canonical binding site. (A) Cartoon/surface 3D-representation of the conserved folded tertiary architecture of an example kinase biotarget; CDK2 (PDB_ID: 1qmz) in complex with ATP molecule (orange sticks), Mg^{+2} ion (green sphere) and protein substrate (cartoon). Key kinase structural motifs and secondary structures are color-coded. The amino and carboxy-termini are denoted with letters N and C, respectively; (B) Detailed ATP-binding site showing the four main sub-pockets (①–④) for the recognition and binding to main scaffolds of the small molecule kinase inhibitors: (C) key pharmacophoric features of reported small molecule kinase inhibitors and the quite superimposition of the spirooxindole scaffolds over these features. Pharmacophoric features are shown in the 3D-spatial arrangement of color-coded meshed spheres (purple = hydrogen bond acceptor HAcc; blue = hydrogen bond donor HDo, and orange = aromatic rings Aro). Arrows denote the projection/directionality of the hydrogen bonds.

harboring purine isosteres are capable of mediating conserved hydrogen bonding towards the hinge region backbone residues. The solvent-exposed hydrophobic region is settled at the kinase pocket entrance, complementary to the non-polar aliphatic/aromatic structures of the kinase inhibitors that are decorated with hydrogen bonding accepting groups. The adenine-specific pocket is covered by a flexible loop endorsed between N-lobe sheets β1/β2 and harboring the glycine-rich structural motif (GXGXφG). The hydrophobic φ amino acid at this conserved

Gly-rich loop provides non-covalent contacts with the ATP phosphates that coin its name as phosphate-binding loop (P-loop). Different kinase structural motifs, including the β3-sheet, conserved VIAK, and activation loop DFG motifs, support the placement of the bridge portion linker region near the kinase gatekeeper. The lysine residue at VIAK has been recognized as important for mediating kinase activation through the salt bridge with ATP phosphate and Cα-helix glutamate. Aspartate of the DFG motif mediates coordination between

Mg^{+2} and ATP phosphates,[67] while the phenylalanine residue either flapped in or out to limit or expand the deep buried hydrophobic region.[68]

Accommodation of these sub-regions, while depicting a conserved interaction towards the hinge region, both have been considered fundamental for developing potent kinase inhibitors.[69] Binding interaction with the αC-helix glutamate sidechain and/or DFG structural motif vicinal to the linker site has been conserved across several FDA-approved kinase inhibitors.[70] Additionally, a deep anchoring of compounds at the back side allosteric hydrophobic sub-pocket in case of DGF out-conformation would permit great compound's potent inhibition and target selectivity for several kinase inhibitors.[71] Based on these molecular binding insights, a common pharmacophoric feature for kinase inhibitors can be proposed, where four main features are required to fulfill the binding requirement at the kinase catalytic pocket (Fig. 2C).[72,73] Following a 3D spatial arrangement, a hydrogen bond acceptor feature is redeemed to satisfy the polar contacts at the solvent-exposed pocket and/or hinge region. This polar feature will be followed by an aromatic pharmacophoric ring resembling the ATP-purine isosteres for settling the kinase inhibitors at the adenine-specific site. A hydrogen bond donor/acceptor feature is to follow to maintain the key polar contacts towards the polar residues (VIAK, αC-helix glutamate, and DFG motifs) at the bridge portion linker. This polar feature is generally associated with urea, hydrazide, or carboxamide structural functionalities reported in several kinase inhibitors. The final pharmacophoric feature of kinase inhibitors is that another aromatic ring is complementary to the deep-buried hydrophobic region. Increasing the size of this terminal aromatic feature has been correlated with deeper anchoring at the allosteric hydrophobic pocket being accessible at DFG-out conformation.[74–76]

Literature reported that spirooxindole-based compounds showed comparable chemical architecture throughout several anti-cancer studies.[77] The design of these reported spirooxindoles is generally based on four main structural aspects. First, an indole or even a thioindole ring is generally considered a relevant bioisostere of the ATP-purine core scaffold. This central indole core ring is suggested as beneficial for mediating hydrogen bonding towards hinge region residues, which could be further augmented by substituting hydrogen bond acceptors

(i.e., fluorine). Such a core ring will be able to fulfill two of the main pharmacophoric features of the small kinase inhibitors at the hinge region and solvent-exposed pocket. The second structural aspect of spiro oxindole-based compounds is spiro cyclization using the saturated fused heterocyclic rings, which would satisfy the hydrogen bonding capability and non-polar contacts at the solvent-exposed hydrophobic site. The saturated property of the spirocyclized ring would introduce a relevant degree of structure flexibility and drug-likeness characteristics, which are valuable during target binding maneuvers and membrane permeation.[78,79]

Furthermore, several reports have highlighted that scraping the flatland by increasing the compounds' three-dimensional conformation would increase the success rates, binding frequencies, and selectivity indices.[80] The spirocyclic ring represents a versatile point for structural diversity, as several reported compounds harbor both substituted aryl and aroyl groups. The aroyl groups fulfill the kinase aromatic and hydrogen bond donor/acceptor pharmacophores through deep anchoring at the buried hydrophobic pocket while maintaining key polar contacts with the linker site polar residues. The aroyl group could be substituted with benzene, fused aromatic rings, or bis-phenyl scaffolds, permitting enhanced anchoring at the kinase back pockets. Regarding the substituted aryl group, it is suggested to depict favored orientation towards the DFG motif permitting hydrophobic and/or π-driven contacts with close residues sidechains. Alignment of the reported spirooxindole scaffolds with the key pharmacophoric features of small molecule kinase inhibitors is shown in Fig. 2C, highlighting a quite relevant overlap.

Chemical synthesis of halogenated spiro-oxindoles

Raposo et al. assessed the antiproliferative activity of selected spiropyrazoline derivatives against A2780 ovarian cancer cells.[13] The synthesis of these compounds, as previously reported in the literature,[81] involved the reaction of indolinone derivatives (1) with imine intermediates (2), which were generated in situ through the dehydrohalogenation of hydrazonyl chloride in the presence of triethylamine (TEA). This process proceeded via a 1,3-dipolar cycloaddition, affording the target spirooxindole derivatives (3a–e) with chemical yields ranging from 76% to 98%, as illustrated in Scheme 1.

3a, R₁ = Br, R₂ = H, R₃ = Ph, R₄ = Ph, R₅ = Ph
3b, R₁ = Br, R₂ = H, R₃ = Ph, R₄ = t-but, R₅ = Ph
3c, R₁ = F, R₂ = Cl, R₃ = 3-Cl-Ph, R₄ = t-but, R₅ = Ph
3d, R₁ = F, R₂ = Cl, R₃ = 2-F,3-Cl-Ph, R₄ = t-but, R₅ = Ph
3e, R₁ = F, R₂ = Cl, R₃ = 2-F,3-Cl-Ph, R₄ = t-but, R₅ = 4-Cl-Ph

Scheme 1 Synthesis of spiropyrazoline derivatives (3a–e).

R_1 = Ph, 4ClPh, 4-FPh, 4ClCH$_2$Ph, 4-tert-butylPh, 4-BrPh, 3-BrPh, 2-Brph, 4-MePh
R_2 = Me, OMe, Cl, Bu
FG =H, CH$_3$, CH$_2$F, CHF$_2$, CH$_2$Br, Si(CH$_3$)$_2$, Bpin

Scheme 2 Synthesis of spirothiooxindoles **6**.

Compound **3a** presented the highest inhibitory effect on the proliferation in the A2780 cell line with an IC$_{50}$ of 8.5 ± 0.7 μM. In normal human primary fibroblasts, cell viability is almost unaffected, except for the highest concentrations, indicating that **3a** is more selective for tumor A2780 cancer cells, as previously observed with this compound in breast and colon cells. Indeed, when exposing fibroblasts to 8.5 ± 0.7 μM of **3a** (its IC$_{50}$ concentration in A2780 cells), no change in viability is observed. Despite the higher IC$_{50}$ of **3a** in ovarian carcinoma compared to the standard chemotherapeutics drugs mentioned, the IC$_{50}$ value is in the low micromolar range (<10 μM).[13,81]

Pan *et al.* synthesized novel spirocyclopropylthiooxindole hybrids featuring a stereochemically rich framework.[82] Their approach involved an enantio- and diastereoselective strategy for the cyclopropanation of diazothiooxindoles **5**, utilizing various Rh-catalyzed α-functionalized alkene systems **4**. The incorporation of diverse substituents on the olefin scaffold facilitated the formation of the target optically active spirooxindoles **6**, bearing a variety of pharmacophores within their skeleton, and achieved excellent chemical yields, as illustrated in Scheme 2.

Compound **6j** with CH$_2$F as a substituent on the cyclopropane ring was the most effective inhibitor of SJSA-1 osteosarcoma cells (IC$_{50}$ = 0.82 ± 0.08 μM), close to six times lower than cisplatin (IC$_{50}$ = 4.85 ± 0.27 μM). Fluorine substitution of the scaffold at R$_3$ also enhanced the activity in comparative cytotoxicity tests on MCF-7 breast cancer cells. Compound **3e**, wherein the R$_1$ and R$_2$ groups remained the same, obtained an IC$_{50}$ value of 1.09 μM, 38 times more potent. More importantly, these compounds exhibited comparatively less cytotoxic effects on normal cells at the same concentrations, offering a promising therapeutic index. These spirooxindole hybrids showed comparable low micromolar cytotoxicity against all cancer types, suggesting that their cytotoxicity values differed, supporting their potential as selective anticancer agents.[82]

Liu *et al.* synthesized a novel series of 3′-(nitroisoxazole)spiro [pyrrolidin-3,2′-oxindoles] bearing a CF$_3$ moiety, which were evaluated for their potential as dual inhibitors of GPX4 and MDM2.[83] The synthetic methodology of the most active compound, 6-chloro-3′-(3-methyl-4-nitroisoxazol-5-yl)-4′-phenyl-5′-(trifluoromethyl)spiro[indoline-3,2′-pyrrolidin]-2-one (**9d**), involved a reaction between 3-methyl-4-nitro-5-styrylisoxazole (**7**) and 6-chloro-isatin imine (**8**) in a basic medium of 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU). The reaction yield and time were highly solvent-dependent, with the optimal conditions achieved using dichloromethane (DCM) at room temperature, as shown in Scheme 3.[83]

Compound **9** with strong GPX4 and MDM2 dual inhibition are important targets for breast adenocarcinoma. It inhibited the MDM2-mediated degradation of p53 and decreased GPX4 expression, leading to both ferroptosis and apoptosis in MCF-7 cells (IC$_{50}$ = 0.12 μM). The process was related to ROS generation, lipid peroxidation, and caspase-9 processing. *In vivo*, 3D suppressed xenograft tumor growth in a mouse model without body weight loss. Immunohistochemistry confirmed enhanced p53 and TUNEL signals and reduced Ki-67 and GPX4 on dual suppression. These findings demonstrate that 3D is a selective, multitarget anticancer scaffold with submicromolar potency.[83]

Kanchrana *et al.* designed and synthesized a new analog of spirooxindolo-1,2,4-oxadiazole derivatives *via* a [3 + 2] cycloaddition reaction, employing a green methodology based on ultrasonication techniques.[84] Various solvents and basic media were tested to optimize yield and minimize reaction time. The optimal conditions were achieved when N-hydroxycarbimidoyl chloride **11** and isatin Schiff bases **12** were reacted for 20

Scheme 3 Synthesis of spiro derivative **9d**.

Scheme 4 Synthesis of spirooxindolo-1,2,4-oxadiazoles **12a** and **12b**.

minutes at room temperature under ultrasonication, using CHCl$_3$ as the solvent and TEA as the basic medium, as shown in Scheme 4. The resulting spiro derivatives were evaluated for their potential anticancer activity against six cancer cell lines: SK-OV-3, HeLa, HCT-116, DU-145, A549, and HEK-293.

5-Chloro-3′-(2-chloroquinolin-3-yl)-4′-phenyl-4′H-spiro[indoline-3,5′-[1,2,4]oxadiazol]-2-one (**12a**), 5-chloro-4′-(3-chlorophenyl)-3′-(2-chloroquinolin-3-yl)-4′H-spiro[indoline-3,5′-[1,2,4]oxadiazol]-2-one (**12b**): The compounds **12a** and **12b** exhibited significant activity against cervical cancer HeLa cell line with IC$_{50}$ value 10.75 ± 0.39 μM and 12.43 ± 0.77 μM, respectively.[84]

Barakat *et al.* rationally designed and synthesized a novel series of spiro-indeno[1,2-*b*]quinoxaline derivatives incorporating a benzimidazole moiety.[54] The synthetic approach involved a one-pot, multicomponent [3 + 2] cycloaddition (32CA) reaction of benzimidazolyl chalcones **13** with 11*H*-indeno[1,2-*b*]quinoxalin-11-one **14** and various amino acids, such as octahydroindole-2-carboxylic acid **15**. The reaction was conducted in refluxed methanol for 8 hours, yielding the target spirooxindole derivatives in yields of 59–95% (16, 84%), as shown in Scheme 5.[54]

The IC$_{50}$ value of compound **16** on A549 human lung cancer cells was 0.054 ± 0.008 nM, which was much more potent than the reference drug fluorouracil (IC$_{50}$ = 3.781 ± 0.52 μM). Normal lung fibroblasts (Wi-38) were 20–40 times less sensitive at this concentration, indicating significant selectivity towards cancer cells. This selectivity aligns with previous reports of spirooxindole compounds featuring benzimidazole and indenoquinoxaline moieties. Notably, normal fibroblasts did not exhibit significantly decreased viability at doses effective for A549 cells, indicating high selectivity of compound 16 against CDK2 and suggesting it is a potential anti-lung cancer drug

candidate. The IC$_{50}$ was shown to be in the nanomolar range, indicating a promising lead compound with high potency and low cytotoxicity toward normal cells.[54]

Korotaev *et al.* successfully carried out a regio- and stereoselective synthesis of a series of *N*-unsubstituted 3-aryl-4-(trifluoromethyl)-4*H* spiro[chromeno[3,4-*c*]-pyrrolidine-1,3′-oxindoles] (**21a–l**) through two synthetic approaches.[85] The first approach involved a one-pot, three-component reaction employing isatin derivatives (**17**), 3-nitro-2-(trifluoromethyl)-2*H*-chromenes (**18**), and benzylamines (**19**). The reaction was optimized under reflux conditions in CH$_2$Cl$_2$ for 24 hours in the presence of a basic medium of 1,4-diazabicyclo[2.2.2]octane (DABCO), yielding the desired spiro derivatives (**21a–l**) with yields ranging from 24% to 79%, as shown in Scheme 6. The second synthetic approach involved a one-pot reaction of the chromene derivatives (**18**) with the azomethine ylides produced *in situ* by the reaction of the isatin derivatives (**17**) with L-phenyl glycine (**20**). The reaction was carried out in EtOH at 60 °C for 5 hours to produce the target spiro derivatives (**21a–l**) with yields between 32% and 71%, as shown in Scheme 6.

The regio- and stereoselective one-pot three-component reaction synthesized compounds **21a**, **21e**, and **21l**, which displayed significant cytotoxicity towards HeLa cervical cancer cell lines. Compound **21l** was the most potent compound, with an IC$_{50}$ value of 0.71 ± 0.05 μM, and thus is greater than that of the reference camptothecin (IC$_{50}$ = 1.66 ± 0.97 μM). Also, **21a** and **21e** were highly active, with IC$_{50}$ = 1.74 ± 0.45 and 1.62 ± 0.52 μM, respectively. Notably, the three candidates demonstrated strong selectivity for cancer cells, and cytotoxicity tests revealed low toxicity towards normal human dermal fibroblasts (HDF) at the IC$_{50}$ of each drug. This selectivity, combined with their low micromolar cytotoxic activities, qualifies these spirooxindole analogs as potential anticancer agents, especially for the

— Bond formation

16, 84%

Scheme 5 Synthesis of spirooxindole **16**.

Scheme 6 Synthetic routes of spirooxindole derivatives (**21a–l**).

selective attack of cervical cancer cells with low side effects on normal tissue.[85]

Al-Majid *et al.* developed a one-pot synthetic method to create a new series of di-spirooxindole derivatives featuring a cyclohexanone moiety *via* 32CA reaction.[86] In this process, isatins (**22a–f**) and (*2S*)-octahydro-1*H*-indole-2-carboxylic acid **23** were reacted to generate azomethine ylides *in situ*, which were then reacted with cyclohexanone-based chalcones (**24a–f**) to yield the target di-spirooxindole derivatives (**25a–n**), as illustrated in Scheme 7.

Although all the tested compounds exhibited significant antiproliferative properties against the PC3 human prostate cancer cell line, the synthesized di-spirooxindole derivative **25b** displayed the highest activity with an IC$_{50}$ of $3.7 \pm 1.0 \mu M$ in the low micromolar range. Compounds **25e** and **25d** exhibited profound cytotoxicity in cervical (HeLa) and triple-negative breast carcinoma (MDA-MB231) cancer cell lines, with IC$_{50}$ values of 7.2 ± 0.5 and $7.63 \pm 0.08 \mu M$, respectively. These

compounds were also highly selective between (at equivalent concentrations) normal and cancer cellular cytotoxicity. The structural rigidity of the di-spirooxindole skeleton may be responsible for the high affinity and selectivity for tumor-related targets. The potential dual antitumor effects in several cancers indicate the practical importance of this scaffold for probing into more anticancer drugs.[86]

Barakat *et al.* reported synthesizing a novel series of spirooxindole derivatives featuring thiochromene and pyrrolidine frameworks.[87] The synthetic approach involved the formation of azomethine ylides through the condensation of ʟ-proline with various isatin derivatives. These intermediates were subsequently reacted with various chalcones incorporating thiochromene scaffolds *via* a 1,3-dipolar cycloaddition reaction, forming the desired spirooxindole derivatives, as depicted in Scheme 8.

1′-(4-Chloro-2*H*-thiochromen-3-yl)-5-fluoro-2′-(4-fluorobenzoyl)-1′,2′,5′,6′,7′,7a′-hexahyd rospiro[indoline-3,3′-pyrrolizin]-2-one (**28d**), 1′-(4-chloro-2 *H* -thiochromen-3-yl)-5-fluoro-2′-(4-nitrobenzoyl)-1′,2′,5′,6′,7′,7a′-hexahydr ospiro[indoline-3,3′-pyrrolizin]-2-one (**28f**), 5-chloro-1′-(4-chloro-2*H*-thiochromen-3-yl)-2′-(4-(trifluoromethyl)benzoyl)-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizin]-2-one (**28k**): The anticancer assay showed promising results as good candidates for further studies. Compounds (**28f**, IC$_{50}$ = $8.7 \pm 0.7 \mu M$) exhibited more potent activity against PC3, whereas hybrid (**28k**) was most active against cervical cancer HeLa (IC$_{50}$ $8.4 \pm 0.5 \mu M$) and for breast cancer MCF-7 cell lines (**28d**, IC$_{50}$ = $7.36 \pm 0.37 \mu M$), whereas (**28d**, IC$_{50}$ = $9.44 \pm 0.32 \mu M$) also appeared more active against MDA-MB231 breast cancer cell line.[87]

Aziz *et al.* employed an efficient synthetic strategy to design two novel spirooxindole derivatives targeting the p53–MDM2 interaction, which downregulates Bcl-2 signaling.[53] The regio- and stereoselective approach involved the reaction of *N*-methyl-2-acetylpyrrole with substituted benzaldehydes *via* an aldol condensation reaction, yielding the corresponding *N*-methyl pyrrole chalcones (**29a–b**). These chalcones were subsequently subjected to a one-pot 32CA reaction with 5-chloroisatine and sarcosine/thioproline, resulting in the formation of the desired spirooxindole derivatives (**30a and 30b**), as depicted in Scheme 9.

Scheme 7 Synthesis of di–spirooxindole derivatives (**25a–n**).

	R$_1$		R$_2$
22a	H	**24a**	H
22b	6-Cl	**24b**	4-Br
22c	5-F	**24c**	3-Br
22d	5-NO$_2$	**24d**	3-F
22e	5-MeO	**24e**	4-F
22f	5-Me	**24f**	4CF$_3$

Scheme 8 Synthesis of spirooxindole derivatives (**28a–m**).

(3*S*,6′*R*,7′*S*)-5-Chloro-6′-(1-methyl-1*H*-pyrrole-2-carbonyl)-7′-(3-nitrophenyl)-1′,6′,7′,7a′-tetrahydro-3′*H*-spiro [indoline-3,5′-pyrrolo [1,2-*c*]thiazol]-2-one (**30b**): compound **30b** showed significant anticancer activities *via* p53–MDM2 interaction and Bcl2 signaling, respectively. In MDA-MB-231 breast cancer cells, it induced p53 activation (47%), downregulation of the Bcl2 gene (1.25-fold), upregulation of p21 (2-fold), and 43.08% apoptosis, which was greater than 5-FU. For all cell lines, including MDA-MB-231, HepG2, and Caco-2, their IC_{50} values were in the low micromolar range, compared with 5-FU (IC_{50} = 7.4 μM). Molecular docking confirmed selective binding to the MDM2 pocket, stabilizing p53. This dual-target effect, simultaneously inhibiting antiapoptotic Bcl2 and reactivating tumor suppressor p53, positions compound **30b** as a multitarget lead scaffold with potential for broad-spectrum anticancer therapy and minimal toxicity to normal cells.[53]

Mayakrishnan *et al.* reported the synthesis of new spirooxindole hybrids *via* a highly efficient and environmentally friendly *in situ* 1,3-dipolar cycloaddition reaction.[88] This synthetic strategy entailed a one-pot reaction of quinoline-pyridine and quinoline-indole-based chalcones (**31** and **33**)

with 5-bromoisatine derivatives in the presence of amino acids thioproline and sarcosine. The method demonstrated exceptional efficacy, producing the desired spirooxindole derivatives (**32** and **34**), respectively, with remarkable yields (88–90%), as illustrated in Scheme 10.

(3*S*,6′*R*,7′*R*)-5-Bromo-1-ethyl-6′-(1*H*-indole-3-carbonyl)-2-oxo-7′-(pyridin-3-yl)-1′,6′,7′,7a′-tetrahydro-3′*H*-spiro[indoline-3,5′-pyrrolo[1,2-*c*]thiazole]-6′-carbonitrile (**32**), and (3*S*,3′*R*,4′*R*)-5-bromo-3′-(1*H*-indole-3-carbonyl)-1′-methyl-2-oxo-4′-(quinolin-3-yl)spiro[indoline-3,2′-pyrrolidine]-3′-carbonitrile (**34**): molecular docking results: **32** and **34** display excellent efficiency in inhibiting the Bcl-2 receptor. Among all the screened compounds, **32** and **34** displayed substantial cytotoxic activity against HepG-2 cells at less than 10 μg mL^{-1}, with IC_{50} values of 9.0 and 8.0 μg mL^{-1}, respectively. Molecular docking studies with the Bcl-2 receptor revealed that a higher binding energy was observed for **32** and **34**, with a value of 6.56 and 8.41 kcal-mol^{-1}, respectively.[88]

Rajaraman *et al.* synthesized a new series of spirooxindole derivatives and evaluated their antioxidant activity against hydroxyl and superoxide radicals.[89] The synthetic strategy

Scheme 9 Synthesis of spirroxindole derivatives **30a–b**.

**Scheme 10** Synthesis of spirooxindole derivatives **32** and **34**.

involved the *in situ* generation of an azomethine ylide (AY) *via* the decarboxylative condensation of isatin **1** and 2-(piperazin-1-yl)ethanamine **2**. These reactive intermediates were then undergoing 1,3-dipolar cycloaddition reaction with various chalcones, leading to the formation of the target spirooxindole derivatives (**37a–g**), as depicted in Scheme 11.[89]

Both compounds **37d** and **37f** were identified as promising candidates for their anticancer efficacy against KB oral cancer cells. As indicated, for compound **37f**, an excellent cytotoxic potency was obtained (IC$_{50}$ = 9.5 µM), whereas compound **37d** exerted only moderate inhibitory activity (IC$_{50}$ = 32.5 µM). Despite the slightly elevated IC$_{50}$ value for **37d**, both compounds represent the overall potential of the spirooxindole scaffold to target epithelial-originated cancers. Notably, the structural diversity afforded by the 1,3-dipolar cycloaddition approach resulted in the selectivity of the tested compounds, which preserved low toxic effects on non-cancer cells even at these concentrations. The data indicate that **37f**, which possesses sub-micromolar potency for the mechanism of action, has great potential for further structural and preclinical development as a highly selective anticancer drug.[89]

De Azevedo *et al.* successfully synthesized a novel series of 25 spirooxindole hybrids integrating phenylamino-pyrimidine-

pyridine (PAPP) and isatin scaffolds, designed as potential anti-myeloproliferative agents against K562 cells.[90] The synthetic pathway involved the condensation of PAPP with various isatin derivatives (**38a–e**) to form the corresponding Schiff base intermediates (**38a–e**), which were subsequently subjected to a 1,3-dipolar cycloaddition reaction with chloro-oxime (**39**). This approach yielded the target spirooxindole derivatives (**40a–e**) in good yields (64–86%), as illustrated in Scheme 12.

5-Fluoro-4′-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl) methyl)phenyl)-3′-(*p*-tolyl)-4′H-spiro[indoline-3,5′-[1,2,4] oxadiazol]-2-one (**40a**), 5-fluoro-3′-(4-fluorophenyl)-4′-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)methyl)phenyl)-4′H-spiro [indoline-3,5′-[1,2,4]oxadiazol]-2-one (**40b**), and 5-bromo-4′-(4-fluorophenyl)-3′-(4-methyl-3-{[4-(pyridin-3-yl)   pyrimidin-2-yl] amino}phenyl)-1,2-dihydro-3′H-spiro[indole-3,2′-   [1,3,5] oxadiazol]-2-one (**40e**): spirooxindole derivatives with a phenyl-amino-pyrimidine-pyridine (PAPP) skeleton were tested for *in vitro* anti-leukemic activity in the chronic myelogenous leukemia line K562. Thirty-six compounds (**40a–e**) elicited significant antiproliferative activities against the EJ, LCFF, and SiHa cell lines, with the most potent CC$_{50}$ value of 0.8 µM for compound **40c**, closely followed by compound **40a** (CC$_{50}$ = 9.6

Scheme 11 Synthesis of spirooxindole derivatives (**37a–g**).

X_1 = H, Me, OMe, F, Cl, Br, NMe$_2$

Scheme 12 Synthesis of spirooxindole derivatives (40a–c).

μM) and compound **40b** ($CC_{50} = 9.8$ μM). These compounds also exhibited reasonable selectivity indices, indicating that they preferentially killed cancer cells compared to normal cells. Incorporating pyrimidine-pyridine moieties appears to have enhanced kinase-related inhibition, which aligns with the reported mechanisms of leukemia therapeutics. The sub-micromolar to low micromolar IC_{50} activity of 40c primarily supports the suitability of this scaffold for development toward targeted anti-myeloproliferative agents.[90]

Alshahrani *et al.* synthesized a novel series of spirooxindole derivatives incorporating a benzimidazole moiety.[91] These compounds were regio- and stereoselectively obtained *via* a multicomponent one-pot [3 + 2] cycloaddition (32CA) reaction. The process involved the formation of an azomethine ylide intermediate through the reaction of 5-chloroisatin with (2S)-octahydro-1*H*-indole-2-carboxylic acid **42**, followed by subsequent coupling with various chalcones **41a–o** featuring the benzimidazole framework. This strategy yielded the targeted

spirooxindoles **43a–o** as cycloadducts with four asymmetric centers, as depicted in Scheme 13.

The anticancer reactivity for the tested compounds showed IC_{50} (μM) in the range between 3.80–6.88 μM, and compound (**43d**) with $IC_{50} = 3.80 \pm 0.21$ μM was the most active candidate between the series.[91]

Islam *et al.* developed a novel series of spirooxindole derivatives featuring a spiro[3*H*-indole-3,2′-pyrrolidin]-2(1*H*)-one framework conjugated to a pyrazole moiety, aiming to explore their potential as MDM2 inhibitors.[14] The synthesis strategy involved the *in situ* formation of an azomethine ylide through the reaction of isatin with L-thioproline, followed by a one-pot multicomponent [3 + 2] cycloaddition reaction with various chalcones (**44a–o**). This approach efficiently yielded the desired spirooxindole derivatives (**45a–o**), as illustrated in Scheme 14.[14]

A new series of spirooxindoles (**45a–o**) was prepared to investigate their anti-MDM2 properties and *in vitro* anti-tumorigenic activity on various cell lines. Some of the compounds tested, such as **45h**, were also found to have potent

43a; Ar = 4-ClC$_6$H$_4$, **43b**; Ar = 4-CF$_3$C$_6$H$_4$, **43c**; Ar = 4-MeC$_6$H$_4$
43d; Ar = thiophen, **43e**; Ar = 4-FC$_6$H$_4$, **43f**; Ar = 2,4-diClC$_6$H$_4$
43g; Ar = 3-OHC$_6$H$_4$, **43h**; Ar = 3,4,5-triCH$_3$OC$_6$H$_2$, **43i**; Ar = 2-OHC$_6$H$_4$;**43j**; Ar = 4-N(CH$_3$)$_2$C$_6$H$_4$, **43k**; Ar = 4-BrC$_6$H$_4$, **43l**; Ar = 3-FC$_6$H$_4$; **43m**; Ar = Furan, **43n**; Ar = 4-NO$_2$C$_6$H$_4$, **43o**; Ar = 3-NO$_2$C$_6$H$_4$

Scheme 13 Synthesis of spirooxindole derivatives (43a–o).

Scheme 14 Synthesis of spirooxindole derivatives (**45a−o**).

cytotoxic activity against A2780 ovarian cancer cells (IC$_{50}$ = 10.30 ± 1.10 μM), and **45m** was very active against A549 lung cancer cells (IC$_{50}$ = 17.70 ± 2.70 μM). Compound **45k** was also active against MDA-MB-453 breast cancer cells with an IC$_{50}$ value of 21.40 ± 1.30 μM. These compounds showed improved p53-induced apoptotic activity due to their structural complementarity of the p53–MDM2 interaction pocket. The IC$_{50}$ values were only moderate, in the micromolar range, and the selectivity against cancer cells, along with the ability to restore p53 tumor suppression, indicate this group's potential, especially in multi-target cancer treatment approaches.[14]

Korotaev *et al.* successfully employed a regio- and stereoselective approach to synthesize novel spiro[chromeno[3,4-*c*]pyrrolidine-1,3′-oxindoles].[85] The optimized reaction conditions involved a three-component, one-pot reaction of a chromene derivative (**9a–g**), isatin derivatives (**11a–f**), and a benzylamine derivative (**12**) in the presence of MgSO$_4$, using CH$_2$Cl$_2$ as the solvent at 40 °C for 24 hours. This method yielded the desired spirooxindole derivatives (**14a–l**) with a maximum chemical yield of 79%, as depicted in Scheme 15.

The *N*-unsubstituted 3-aryl-4-(trifluoromethyl)-4*H*-spiro[chromeno[3,4-*c*]pyrrolidine-1, 3′-oxindoles] prepared showed extremely potent anticancer activities, especially against HeLa

cervical cancer cells. Compounds **48d**, **48j**, and **48l** were highly potent, and the IC$_{50}$s were lower than that of the reference drug camptothecin, with **48l** emerging as the most potent (IC$_{50}$ = 0.71 ± 0.05 μM). The derivatives exerted their effect predominantly by inhibiting cancer cell proliferation and exhibited a high degree of selectivity, with little or no toxicity to normal human dermal fibroblasts (HDF). The primary molecular targets are atherosclerosis and inflammation, while the cell cycle and apoptotic pathways are affected through the use of the trifluoromethyl group. The spiro-oxindole core ensures the required regio- and stereoselectivity, which is important for bioactivity, demonstrating strong potential for the treatment of cervical and perhaps other cancers.[85]

Kumar *et al.* designed and synthesized a novel spirooxindole derivative incorporating a pyrrolidine motif using a one-pot [3 + 2] cycloaddition reaction.[92] The synthesis protocol began with *N*-Alkylation of *N*-unsubstituted bisarylmethylidene-tetrahydropyridinone hybrids (**49a–h**) with 2-(chloromethyl)pyridine hydrochloride, affording the desired chalcones (**50a–h**) in high yields (85–90%). In the next steps, (**5a–h**) underwent a one-pot cycloaddition reaction with an azomethine ylide, generated *in situ* via the decarboxylative condensation of isatin with phenylglycine. This approach efficiently yielded the target

48a, R$_1$ = R$_2$ = R$_3$ =R$_4$ =H; **48b**, R$_1$ = Me, R$_2$ = R$_3$ =R$_4$ =H
48c, R$_1$ = OMe, R$_2$ = R$_3$ = R$_4$ =H; **48d**, R$_1$ = Br, R$_2$ = R$_3$ =R$_4$ =H
48e, R$_1$ = Br, R$_2$ = Br, R$_3$ =R$_4$ =H; **48f**, R$_1$ = Br, R$_2$ = OEt, R$_3$ =R$_4$ =H
48g, R$_1$ = NO$_2$, R$_2$ = R$_3$ =R$_4$ =H; **48h**, R$_1$ = R$_2$ = R$_3$ = H, R$_4$ =Me
48i, R$_1$ = R$_2$ = R$_3$ = H, R$_4$ = Br; **48j**, R$_1$ = R$_2$ = H, R$_3$ = Me, R$_4$ = H
48k, R$_1$ = R$_2$ = H, R$_3$ = Et, R$_4$ = H; **48l**, R$_1$ = R$_2$ = H, R$_3$ = Bn, R$_4$ = H

Scheme 15 Synthesis of spirooxindole derivatives **48a−l**.

Scheme 16 Synthesis of spirooxindole derivatives (**8a–h**).

novel spirooxindole derivatives (**51a–h**), as illustrated in Scheme 16.

A new family of spirooxindole derivatives featuring a pyrrolidine nucleus has been prepared and tested for their time-dependent antiproliferative potential. Of these, compound **51f** showed the most potent activity at 24 h, with an IC_{50} of approximately 43.46 μg mL^{-1}. However, after 48 h on the trend line, **51c** turned out to be the most effective of the active compounds, **51g**, with an IC_{50} of around 12.79 μg mL^{-1}, and time exposure showed a time-dependent increase in cytotoxic activity. While these IC_{50} values are higher than other low-micromolar hits, their potency increases over time, reflecting a possible cumulative or delayed mode of action. These results suggest that continued pharmacokinetic and structural optimization will be necessary to achieve sufficient potency and selectivity for effective anticancer use.[92]

Nafie *et al.* designed and synthesized a novel series of pyrrolidinyl-bis-spirooxindole-based rhodanine hybrids as potential anti-breast cancer agents.[8] Following the reported method, the synthesis strategy involved utilizing previously

Scheme 17 Synthesis of bi-spirooxindole derivatives **54a–o**.

prepared chalcones **52a–f**, which incorporated a rhodanine moiety.[93] These chalcones were then subjected to a one-pot [3 + 2] cycloaddition reaction with isatin derivatives **53a–e** and thioproline, leading to the formation of the target bis-spirooxindole derivatives **54a–o**, as illustrated in Scheme 17.

2-((3S,6′S,7′S,7a′S)-5-Bromo-7′-(4-chlorophenyl)-2,2″,4″-trioxo-7′,7a′- dihydro-1′H,3′H-dispiro [indoline-3,5′- pyrrolo [1,2-c] thiazole-6′,5″-thiazolidin]-3″-yl)acetic acid **54g**, methyl (2-((3S,6′S,7′S,7a′S)-7′-(4-bromophenyl)-6-chloro-2,2″,4″-trioxo7′,7a′-dihydro-1′H,3′H-dispiro [indoline3,5′-pyrrolo [1,2-c] thiazole-6′,5″- thiazolidin]-3″-yl)acetyl)valinate **54l**, methyl (2-((3S,6′S,7′S,7a′S)-6-chloro-7′-(4-   chlorophenyl)-2,2″,4″-trioxo-7′,7a′- dihydro-1′H,3′H-dispiro [indoline-3,5′-pyrrolo [1,2-c]thiazole-6′,5″-thiazolidin]- 3″-yl)acetyl)alaninate **54n** [8,93]. A new class of bis-spirooxindole derivatives (**54a–o**) with a pyrrolidinyl-thiazolidine skeleton was developed to provide a structure with improved anticancer activity. Compound **54g** displayed the most potent cytotoxicity against MCF-7 and MDA-MB-231 breast cancer cells, with IC$_{50}$ values of 2.80 μM and 23.50 μM, respectively. Compounds **54l** and **54o** also demonstrated markedly potent activities with IC$_{50}$ values in the range of 3.40–4.50 μM toward MCF-7 and 4.30–8.40 μM toward MDA-MB-231. Compounds **54g**, **54l**, and **54n** were especially selective with IC$_{50}$ of >39 μM in WISH normal cells. Moreover, compounds **54l** and

54n (with the validate and alaninate moieties, respectively) also showed good activity toward both MDA220-231 and HeLa cancer cell lines. These compounds also demonstrated potent dual EGFR and CDK-2 inhibition, and **54g** significantly induced apoptosis in MCF-7 cells, confirming their promise as targeted anticancer agents.[8]

Shawish *et al.* synthesized triazole-spirooxindole derivatives and evaluated their anticancer potential against HepG2 and MDA-MB-231 cell lines.[94] The initial synthetic approach aimed to construct chalcones featuring a triazole-*s*-triazine framework (**57a–d**)′; however, the triazine moiety was unexpectedly cleaved during the reaction, resulting in chalcones conjugated solely to the triazole motif as shown in Scheme 18. These chalcones **58a–d** subsequently underwent a [3 + 2] reaction with an azomethine ylide (AY), generated *in situ* via the decarboxylative condensation of isatin derivatives **59a–c** with Thioproline. This multicomponent reaction efficiently produced nine spirooxindole derivatives (**60a–i**), as illustrated in Scheme 18.

In this series of the prepared compound **60h**, which contains a 2,4-dichlorophenyl substituent, is the most potent cytotoxic agent against MDA-MB-231 and HepG2 cell lines with IC$_{50}$ values of 16.80 ± 0.37 and 17.00 ± 0.13 nM, respectively. Moreover, compound **60i** showed significant activity with IC$_{50}$ 18.5 ± 0.74 μM against MDA-MB-231 and 13.50 ± 0.92 μM

Scheme 18 Synthesis of spirooxindole derivatives (**60a–i**).

against HepG2. Molecular docking studies of **60h** confirmed good binding interactions in the EGFR active site, indicating a potential for dual inhibition. Even though these analogs are weaker than sorafenib ($IC_{50} = 2.60$ μM for HepG2), they show significant selectivity and structural flexibility, from which their development as EGFR inhibitors in anticancer therapy can be pursued.[94]

A novel series of spirooxindole derivatives incorporating pyrrolothiazolidine and an additional structural framework[16] was developed by Zhao *et al.* as dual MDM2/HDAC inhibitors for cancer therapy. The synthesis began with generating azomethine ylides *via* the condensation of secondary amino acids, such as thioproline, sarcosine, proline, and phenyl glycine, with substituted isatin derivatives. These intermediates were then subjected to a [3 + 2] cycloaddition reaction with various ethylene derivatives, yielding the target spirooxindole derivatives, as illustrated in Scheme 19. The nitro group on the benzene ring was subsequently reduced to an amine, which was then coupled with acid-linker derivatives representing the HDAC pharmacophore using peptide coupling reagents like HATU/DIEPA. The final step involved hydrolysis to produce the desired compounds, among which compound **65** emerged as the most active. Compound **65** exhibited significant inhibitory activity against MDM2 and HDAC, with 68% and 79% inhibition rates, respectively. Additionally, it demonstrated potent antiproliferative effects against MCF-7 cells, outperforming the reference drugs SAHA and Nutlin-3 in terms of efficacy.[16]

The spirooxindole-based dual inhibitors were among the most potent compounds of the synthesized series; compound

65 was more potent ($IC_{50} = 1.37 \pm 0.45$ μM) than hydroxamate (3.13 ± 0.78 μM) and Nutlin-3 (9.75 ± 2.97 μM) against MCF-7 breast cancer cells. It also exhibited strong enzyme inhibition activities, with 68% MDM2 and 79% HDAC inhibition. Compound **65** displayed selective inhibition against HDAC1 and HDAC2 ($IC_{50} = 0.058$ and 0.064 μM, respectively), and molecular docking studies confirmed strong binding to MDM2 and HDAC1. In addition, the expression of p53 and the acetylation of histone H4 were strongly induced by compound **65**, leading to apoptosis in MCF-7 cells. These results suggest that compound **65** may be regarded as a promising anti-cancer agent for the simultaneous inhibition of HDAC and MDM2.[16]

El-Kalyoubi *et al.* developed a novel series of spirooxindole derivatives incorporating pyrimidines and *in situ* selenium nanoparticles (SeNPs) for certain derivatives Scheme 20,[60] designed as dual Topo I/II inhibitors for cancer therapy. The synthesis commenced with the cyclo condensation of cyclic enaminones **66a,b** with 6-chloroisatin, yielding polyheterocyclic spirocompounds **67a,b**, as outlined in Scheme 20. The research team aimed to synthesize new SeNPs **68a** NPs and **68b** NPs, which exhibited suitable low reducing but high stabilizing properties during SeNPs formation. These organic heterocycle derivatives facilitated the reduction of Se^+ cations to Se^0 using ascorbic acid as a catalyst, which acted as an aldehyde equivalent to generate and stabilize the nanostructure of SeNPs. The designed compounds were also engineered to function as DNA intercalators.[60]

Thirteen spirooxindole-based compounds, particularly the nanoformulated hybrids **68a** NPs and **68b** NPs, were evaluated

**Scheme 19** Synthesis of spirooxindoles **65**.

Scheme 20 Synthesis of spirooxindoles **68**.

in vitro against a panel of five human cancer cell lines (HepG2, HCT-116, Caco-2, A-549, and MCF-7). Both nanoparticles exhibited potent cytotoxic effects, with IC_{50} values ranging from 1.9 ± 0.1 µg mL^{-1} to 18.9 ± 2.4 µg mL^{-1}. Mechanistically, compound **68a** NPs and **68b** NPs exhibited potent inhibition against topoisomerase I ($IC_{50} = 0.119$ µM and 0.042 µM) and topoisomerase II ($IC_{50} = 4.469$ µM and 1.172 µM) in both cases. Compound **68b** NPs also significantly triggered S-phase cell cycle arrest and apoptosis in A549 lung cancer cells, suggesting them as dual-function anticancer agents that can intercalate with DNA and inhibit enzyme activity. These data highlight the potential therapeutic significance of SeNP and spirooxindole conjugates, as well as their cytotoxicity profile against different cancer cell lines due to the multi-mechanistic modes of action that target DNA topology and cell cycle progression.[60]

Ashraf *et al.* designed and synthesized a novel series of spirooxindole derivatives featuring a pyrazole motif (Scheme 21),[95] targeting Ecto-5′-Nucleotidase (ecto-5′-NT) inhibitors for cancer therapy.[95] The synthesis involved a one-pot, three-component reaction using equimolar amounts of isatin **69a–f**, malononitrile, and substituted 3-aminopyrazoles **70a,b** as shown in Scheme 21. The reaction was conducted at 100 °C on a sand bath in a reaction flask, yielding twelve spiroindoline-pyrazolo[3,4-*b*]pyridine derivatives **71a–l**. These compounds were evaluated for their inhibitory activity against purified recombinant human and rat ecto-5′-NT isozymes. Among the synthesized derivatives, compound **71f** (R=F$_3$CO) emerged as a potent inhibitor of human ecto-5′-NT, exhibiting an IC_{50} value of 0.15 $\pm$ 0.02 µM. This compound demonstrated a remarkable 280-fold greater inhibitory potency compared to the reference standard, sulfamic acid, highlighting its potential as a promising candidate for further development in cancer therapy.[95]

An *in vitro* biological study of these compounds was the inhibition of the recombinant human and rat ecto-5′-NT isozymes, which have recently emerged as targets for cancer immunotherapy. Compound **71f**, which has a trifluoromethoxy (F$_3$CO) group, seemed to be the most potent inhibitor within the series with an IC_{50} value of 0.15 $\pm$ 0.02 µM towards human ecto-5′-NT. This *in vitro* potency represents a 280-fold improvement *versus* reference sulfamic acid, demonstrating a significant structural advance on the scaffold. The more potent inhibitory activity is ascribed to the F$_3$CO group as an electron-withdrawing substituent, causing better binding at the enzyme's active site. This discovery positions the pyrazole-linked spirooxindoles as promising drug candidates for future anti-cancer research, particularly in approaches that target purinergic signaling in the modulation of tumor immunosuppression.[95]

Zhou *et al.* successfully designed and synthesized a novel series of 5′-CF$_3$-substituted 3,2′-pyrrolidinyl spirooxindoles with high yields (up to 89%) and high diastereoselectivities (>99 : 1 dr) and exceptional diastereoselective 1,3-dipolar [3 + 2] cyclo-addition of *N*-2,2,2-trifluoroethylisatin-based ketimines with chalcones facilitated by DBU.[96] These compounds were evaluated for their *in vitro* anticancer potential. The synthesis pathway was conducted through a Michael/Mannich-type cascade in which azomethine ylides were generated through a DBU-promoted method. The synthesis utilized a one-pot, two-component reaction involving *N*-2,2,2-trifluoroethylisatin keti-mines **72** and various activated alkenes **73** through a [3 + 2] cycloaddition reaction. This cyclization process was carried out smoothly in ethyl acetate (EtOAc) at 28 °C using DBU as a cata-lyst, resulting in the production of twenty-four 5′-CF$_3$-substituted 3,2′-pyrrolidinyl spirooxindole derivatives **74** as shown in Scheme 22.[96]

The antitumor activity of the prepared compounds was tested *in vitro* against human gastric cancer SCG7901 cells through MTT assay. Among selected compounds, **74(b, d, g, h, l, x)** demonstrated cytotoxicity with IC_{50} values ranging from 29.97 to 34.07 µM, which suggested moderate activity. Although not sub-micromolar, the biological data underpin the pharmacological significance of the 5′-CF$_3$ motif and spirooxindole scaffold. These findings confirm synthetic compounds as promising hits that can be used for lead optimization and

Scheme 21 Synthesis of spirooxindoles **71**.

R = H, F, Cl, NO$_2$, OCF$_3$
R$_1$ = H, CH$_3$
R$_2$ = H, CH$_3$

Scheme 22 Synthesis of spirooxindoles 74.

Scheme 23 Synthesis of spirooxindoles 77.

further exploration of structure–activity relationships. Donor–acceptor optimizations are easily synthesized, and as such, their good scaffold flexibility, trifluoromethyl substitution, and synthetic versatility enhance their applications in drug discovery.[96]

Filatov *et al.* successfully designed and synthesized a novel series of bis-aryl spirooxindole-β-lactams through a Staudinger ketene-imine cycloaddition reaction.[97] The synthesis utilized *N*-aryl-2-oxopyrrolidine-3-carboxylic acids **75** as a ketene source to react with isatin derivatives **76**, achieving high yields and excellent diastereoselectivity Scheme 23. The resulting dispirooxindoles **77** Scheme 23 were evaluated for their biological activity, demonstrating moderate cytotoxicity in MTT assays against A549, MCF7, HEK293, and VA13 cell lines.[97]

The cytotoxicity screening of compounds **77a–f** revealed a structure-dependent inhibition of cancer (MCF7, A549) as well as normal cell (VA13, HEK293t) lines. Both compounds **77e** and **77f** showed the highest activity on all tested cancer cell lines with IC_{50} values below 8 μM and were, at the same time, much more active than former mono-spiro analogs. This also suggests that they have higher activity due to the right choice of aryl substitution and the increase in log P values, which affects membrane permeability and target affinity. Moreover, compound **77f** exhibited selective antibacterial potency against

the LPTD strain of *E. coli* (MIC = 1.3 μM), likely due to perturbation of outer membrane permeability. These results indicate that dispirooxindole-β-lactams do not lose and, in several situations, improve the therapeutic profile of the spirooxindole core, and their development as anticancer and antimicrobial leads is warranted.[97]

Ren *et al.* successfully designed and synthesized a new series of spirooxindole–indenoquinoxaline derivatives **78** Scheme 24, which act as inhibitors of tryptophanyl-tRNA synthetase (TrpRS).[98] The synthesis involved a 1,3-dipolar cycloaddition reaction of azomethine ylides, generated *in situ* from isatin and amino acids such as proline, phenyl glycine, and sarcosine. These compounds were evaluated for their biochemical TrpRS inhibitory activity through *in vitro* experiments, testing against various Gram-positive and Gram-negative bacterial strains, as well as diffuse large B-cell lymphoma (DLBCL) cell lines.[98]

Compound **78e** was identified as the most active inhibitor of hmTrpRS and EoffTrpRS (IC_{50} = 225 nM and 74 nM, respectively). It also demonstrated excellent antibacterial activity against *Staphylococcus aureus* (MIC_{90} = 4 μg mL^{-1}). Compound **78e** exhibited significant anti-proliferative activities of 2.97–4.85 μM toward DLBCL cell lines in cancer models while remarkably inducing bacterial autolysis in MRSA strains, suggesting it may be a tool compound for the discovery of dual antibacterial and

Scheme 24 Synthesis of spirooxindoles 78.

Scheme 25 Synthesis of spirooxindoles **79**.

anticancer agents, and structure–activity relationship (SAR) should be improved for the development of potential therapeutic agents.[98]

Fawazy *et al.* successfully designed and synthesized a novel series of 1″-(alkylsulfonyl)-dispiro[indoline-3,2′-pyrrolidine-3′,3″-piperidine]-2,4″-dione derivatives **79**, which exhibit anti-SARS-CoV-2 properties.[99] The synthesis was achieved through a 1,3-dipolar cycloaddition reaction involving azomethine ylides derived from 1-(alkylsulfonyl)-3,5-bis(ylidene)-piperidin-4-ones, generated *in situ* from isatin and amino acids such as proline, phenyl glycine, and sarcosine Scheme 25. These compounds were screened for their activity against several human cancer cell lines, including MCF7, HCT116, A431, and PaCa2, while demonstrating a favorable selectivity index toward normal RPE1 cells.[99]

The dispirooxindole derivatives **79a–m** were evaluated for anticancer, antiviral, and cholinesterase inhibitory activities. Compound **79m** displayed the most potent anti-proliferative impact, equivalent to 5-fluorouracil and sunitinib for the MCF7, HCT116, A431, and PaCa2 cell lines. Moreover, apoptosis and necrosis in the case of compound **79l** with IC$_{50}$ values of 3.60 μM (MCF-7), 3.24 μM (HCT116), and 2.43 μM (A431) and **79m** with IC$_{50}$ = 8.83 μM against PaCa-2 cells were mediated by EGFR and VEGFR-2 inhibition. In anti-SARS-CoV-2 activity, **79k** was also the most potent, with 3.3-fold and 4.8-fold superiority to chloroquine and hydroxychloroquine, respectively. In addition, a handful of the analogs exhibited significant dual activity against AChE and BChE. These results indicate that dispirooxindoles **79** can be regarded as highly promising multitarget therapeutics for cancer, viruses, and neurodegenerative diseases.[99]

Budovská *et al.* report an alternative synthetic approach for producing the anticancer molecule (*S*)-(−)-spirobrassinin and its 2′-amino analogs.[100] The synthesis involves CrO$_3$-mediated oxidative cyclization of chiral derivatives of brassinin, followed by removal of the chiral auxiliary, achieving high enantiomeric purity (93%, ee). Additionally, the study describes a one-step synthesis of 2′-phenylamino analogs of spirobrassinin and 1-methoxyspirobrassinin from thioureas using CrO$_3$ as depicted in Scheme 26. These compounds **80** were evaluated for antiproliferative activity against six human cancer cell lines, with the CF$_3$-containing analogs showing significant potency, particularly against leukemia cells, while exhibiting low toxicity to nonmalignant endothelial cells.

The synthesized spirobrassinin and its (±)-2′-amino analogs were screened against six human cancer cell lines: Jurkat and CEM (T-cell acute lymphoblastic leukemia), MCF-7 and MDA-MB-231 (breast adenocarcinoma), HeLa (cervical carcinoma), and A-549 (non-small cell lung carcinoma). The parent molecule spirobrassinin (±)-3 showed weak activity (IC$_{50}$ > 100 μM) across all lines except Jurkat (IC$_{50}$ = 63.4 μM). Amino analogs (±)-41 to (±)-46 exhibited selective activity primarily toward leukemic cell lines, especially Jurkat and CEM (*e.g.*, (±)-44 had IC$_{50}$ = 27 μM on Jurkat, 34 μM on CEM). Importantly, 47 (±) and 48 (±) with CF$_3$ and bis-CF$_3$ groups displayed broad-spectrum potency against all cancer cell lines tested, IC$_{50}$ 26.1–35.5 μM. For instance, compound **80** derivatives [(±)-47] were active to IC$_{50}$ = 26.1 μM (Jurkat), 33.6 μM (MCF-7 & HeLa), and 32.2 μM (A-549) while not toxic towards the normal cells HUVEC (IC$_{50}$ > 100 μM). These data highlight the significant role of trifluoromethyl substitution in improving anti-cancer potency and selectivity.[100]

Odeh *et al.* report the synthesis of new spiro-indoline-pyrazolo[3,4-*b*]pyridines (81a-f) *via* a one-pot, three-component reaction of indoline-2,3-diones with 3-oxo-3-aryl propanonitriles and 1,3-diphenyl-1*H*-pyrazol-5-amine as shown in Scheme 27.[101] The reactions were performed in aqueous acetic acid using reflux to yield the spiro compounds in good yields. The compounds exhibited spiro-fused heterocyclic scaffolds suitable for application in anticancer drug discovery. The simplicity and efficiency of this synthetic approach provide a general

Scheme 26 Synthesis of spirooxindoles **80**.

R = 4-H, 4-F, 4-Cl, 4-Br, 4-Me, 4-MeO, 4-CF$_3$, 3,5-bis-CF$_3$

Scheme 27 Synthesis of spirooxindoles **81f**.

method for structurally diverse frameworks containing oxindole and pyrazolopyridine residues as suitable ligands for protein–protein interactions, such as p53–MDM2, and offer an excellent basis for bioactivity screening.[101]

Compound **81f** was determined to be the most potent compound, showing 3.05 ± 0.12 μM of IC$_{50}$ in the blockade of p53–MDM2 interaction, superior to Nutlin-1 (IC$_{50}$ = 8.21 ± 0.25 μM). western blot analysis showed that **81b**, **81e**, and **81f** up-regulated p53 and p21 protein expressions in leukemia (MOLT-4) and non-small cell lung cancer (HOP92) cell lines. In addition, they were able to cause a high degree of early and late apoptosis of MCF-7 breast cancer cells. Molecular docking analyses revealed that the active compounds could bind favorably in the MDM2 cleft, and their mechanism of action as p53–MDM2 inhibitors could be therapeutically relevant. Screening of the anti-cancer profile of the synthesized spiro-indoline-pyrazolo[3,4-*b*]pyridines 6a–f and 7a–f showed interesting profiles in the NCI-60 human tumor cell lines panel.[101]

Eichhorst *et al.* designed and synthesized a spirooxindole-1,3-oxazines, a class of compounds structurally related to the spirooxindole alkaloid family.[102] The synthetic route started with dioxyreserpine **82**, a naturally occurring spirooxindole alkaloid, as the starting material. Through a sequence of chemical transformations, they generated a diverse set of novel derivatives. These compounds were then evaluated for their anticancer activity against six selected cancer cell lines. Among them, the derivative 10-(4-trifluoromethylphenyl)trioxy-eserpine **85** showed the most promising activity. The synthesis pathway of this potent derivative involved an initial bromina-tion of dioxyreserpine **82** at the C-10 position, yielding compound **83**. This was followed by an aryl substitution reaction to produce compound **84**. Subsequently, selective oxidation of the C–H bond at the C-14 position of (16) under optimized photooxygenation conditions was carried out to get the target spirooxindole **85**, as detailed in Scheme 28.[102]

The spiro-oxindoline compound **85**, a 10-(4-tri-fluoromethylphenyl)trioxyreserpine derivative, had strong anti-tumor activity in 6 human cancer cell lines with selectivity. It demonstrated IC$_{50}$ in the range of 0.61 ± 0.38 μM (NALM-6), 0.32 ± 0.06 μM (RS4; 11), 1.14 ± 0.20 μM (SU-DHL-4), 1.62 ± 0.13 μM (SUP-T1), 1.90 ± 0.88 μM (MIA-PaCa-2), and 4.21 ± 0.95 μM (Capan-1), being more potent than its parent compound dioxyreserpine. Compound **85** significantly reduced metabolic activity and induced apoptosis (up to 82.6% late apoptosis), as confirmed by Annexin-V/PI staining. It also caused G1 phase arrest and cell fragmentation. While its precise molecular targets remain unspecified, its functional modifications at C-10 and C-14 enhance hydrophobic interactions and oxidative stress pathways, contributing to apoptosis and cell cycle disruption. There is no hemolytic activity, illustrating the selectivity and safety. Its effect comprises decreased cell proliferation, increased cell fragmentation, and detritus formation, indicating potent anti-tumor activity for both hematological and solid tumors.[102]

A novel series of spirooxindole derivatives was synthesized by Westphal *et al.* using a green multicomponent domino reaction.[103] These derivatives were subsequently investigated *in vitro* against different cancer cell lines. The microwave-assisted synthesis of the most active derivative in this series **86** involved the reaction of 6-bromo isatin, malononitrile, and barbituric acid in ethanol as the solvent, with 1-methyl-imidazolium chloride serving as the catalyst, as shown in Scheme 29.[103]

In vitro antiproliferative activities of the spirocycles against four types of human cancer cell lines, including HCT116 (human colon carcinoma), PC3 (prostate carcinoma), HL60 (promyelocytic leukemia), and SNB19 (astrocytoma), were screened by MTT-based assay. It is noteworthy that spiro compound 1c inhibited the four cell lines tested with the lowest

**Scheme 28** Synthesis of spirroxindole 85.

IC$_{50}$ values: 52.81 μM for HCT116, 74.40 μM for PC3, 101.00 μM for SNB19, and 49.72 μM for HL60.[103]

More recently, Islam *et al.*, designed a novel spirooxindoles to target NSCLC and bacteria. By combining structural features from marine antitumor and antibacterial agents, a new series of pyrazole-linked spirooxindoles was synthesized Scheme 30.[104]

The marine natural product-inspired compound **90p** showed potent anticancer (towards non-small cell lung carcinoma/NSCLC) and antibacterial (against *Staphylococcus aureus*) dual effects. The TIC was highly cytotoxic in A549 lung cancer cells with IC$_{50}$ 0.042 μM and a selectivity index (SI) of 58.28, which means that they are highly tumor-specific. It also exhibited

Scheme 29 Synthesis of spirroxindole 86.

Scheme 30 Synthesis of spirooxindoles 90a–v to target both NSCLC and bacteria.

Table 1 Therapeutic potential of halogenated spirooxindoles as antiproliferative agents

Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
3a		Cell line A2780	IC$_{50}$ [µM] Treatment 8.50 ± 0.70	Cisplatin 1.90 ± 0.20	Doxorubicin 0.60 ± 0.03	—	13
6J		Cell line SJSA-1	IC$_{50}$ [µM] Treatment 0.82 ± 0.08	Cisplatin 4.85 ± 0.27	—	82
9		Cell line MCF-7	IC$_{50}$ [µM] Treatment 0.12	Nutlin-3 14.63	ML210 0.076	MDM2 and GPX4	83
12a		Cell line HeLa	IC$_{50}$ [µM] Treatment 10.75 ± 0.39	Doxorubicin 1.73 ± 0.08		Histone deacetylases enzyme	84
12b		Cell line HeLa	IC$_{50}$ [µM] Treatment 12.43 ± 0.77	Doxorubicin 1.73 ± 0.08		Histone deacetylases enzyme	84

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
		Cell line	IC$_{50}$ [nM μM^{-1}] Treatment [nM]	Fluorouracil [μM]		
16		A549	0.05 ± 0.01	3.78 ± 0.52	CDK2	54
		Cell line	IC$_{50}$ [μM] Treatment	Camptothecin		
21a		HeLa	1.74 ± 0.45	1.66 ± 0.97	—	85
		Cell line	IC$_{50}$ [μM] Treatment	Camptothecin		
21e		HeLa	1.62 ± 0.52	1.66 ± 0.97	—	85
		Cell line	IC$_{50}$ [μM] Treatment	Camptothecin		
21l		HeLa	0.71 ± 0.05	1.66 ± 0.97	—	85

Table 1 (*Contd.*)

| Cpd no.	Structure	Anti-cancer activity		Molecular target	Ref.
25b		Cell line PC3	IC$_{50}$ [μM] Treatment 3.70 ± 1.00	MDM2	86
			Doxorubicin 1.90 ± 0.40		
25e		Cell line HeLa	IC$_{50}$ [μM] Treatment 7.20 ± 0.50	MDM2	86
			Doxorubicin 0.90 ± 0.14		
25d		Cell line MDA-MB231	IC$_{50}$ [μM] Treatment 7.63 ± 0.08	MDM2	86
			Doxorubicin 0.32 ± 0.00		
28f		Cell line PC3	IC$_{50}$ [μM] Treatment 8.70 ± 0.70	—	87
			Doxorubicin 1.90 ± 0.40		
28k		Cell line HeLa	IC$_{50}$ [μM] Treatment 8.40 ± 0.50	—	87
			Doxorubicin 0.90 ± 0.14		

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
28d		IC$_{50}$ [µM]			—	87
		Cell line	Treatment	Doxorubicin		
		MCF-7	7.36 ± 0.37	0.79 ± 0.05		
		MDA-MB231	9.44 ± 0.32	0.32 ± 0.00		
30b		IC$_{50}$ [µM]			p53–MDM2 and Bcl2	53
		Cell line	Treatment	5-Fluorouracil (5-FU)		
		MDA-MB 231	0.002 ± 0.00	7.05 ± 0.20		
		HepG-2	0.057 ± 0.00	4.83 ± 0.30		
		Caco-2	0.003 ± 0.00	1.05 ± 0.16		
32		IC$_{50}$ [µg mL^{-1}]			Bcl-2	88
		Cell line	Treatment	Cisplatin		
		HepG-2	9.00 ± 0.00	—		
34		IC$_{50}$ [µg mL^{-1}]			Bcl-2	88
		Cell line	Treatment	Cisplatin		
		HepG-2	8.00 ± 0.00	—		

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
37d		IC$_{50}$ [μM]			—	89
		Cell line	Treatment	— —		
		KB	32.50 ± 0.00			
37f		IC$_{50}$ [μM]			—	89
		Cell line	Treatment	— —		
		KB	9.50 ± 0.00			
40a		IC$_{50}$ [μM]		Imatinib	Kinase-related inhibition	90
		Cell line	Treatment	0.08 ± 0.00		
		K562	9.60 ± 0.00			
40b		IC$_{50}$ [μM]		Imatinib	Kinase-related inhibition	90
		Cell line	Treatment	0.08 ± 0.00		
		K562	9.80 ± 0.00			

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
		IC$_{50}$ [μM]		Imatinib	Kinase-related inhibition	90
		Cell line	Treatment			
40c		K562	0.80 ± 0.00	0.08 ± 0.00		
		IC$_{50}$ [μM]		—	—	91
		Cell line	Treatment			
43d		MDA-MB 231	3.80 ± 0.21	—		
		IC$_{50}$ [μM]		Doxorubicin	p53–MDM2	14
		Cell line	Treatment			
45h		A2780	10.30 ± 1.10	7.70 ± 3.90 nM		
		HepG2	18.60 ± 2.40	127.00 ± 18.00 nM		
		IC$_{50}$ [μM]		Doxorubicin	p53–MDM2	14
		Cell line	Treatment			
45m		A549	17.70 ± 2.70	61.30 ± 15.20 nM		

Table 1 (*Contd.*)

| Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
45k		Cell line MDA-MB-453	IC_{50} [μM] Treatment 21.40 ± 1.30	Doxorubicin 178.00 ± 26.00 nM	p53–MDM2	14
48d		Cell line HeLa	IC_{50} [μM] Treatment 0.32 ± 0.05	Camptothecin 1.66 ± 0.97	Atherosclerosis and inflammation	85
48j		Cell line HeLa	IC_{50} [μM] Treatment 0.47 ± 0.04	Camptothecin 1.66 ± 0.97	Atherosclerosis and inflammation	85
48l		Cell line HeLa	IC_{50} [μM] Treatment 0.71 ± 0.05	Camptothecin 1.66 ± 0.97	Atherosclerosis and inflammation	85
51f		Cell line HepG2	IC_{50} [μg mL^{-1}] Treatment 43.46 ± 2.10	Melphalan —	—	92

Table 1 (*Contd.*)

Cpd no.	Structure	Anti-cancer activity				Molecular target	Ref.
51g			IC$_{50}$ [µg mL^{-1}]	Melphalan		—	92
		Cell line	Treatment	—			
		HepG2	12.79 ± 2.60				
54g			IC$_{50}$ [µM]	Erlotinib		EGFR CDK2	8
		Cell line	Treatment	2.14 ± 0.30			
		MCF-7	2.80 ± 0.40	3.25 ± 0.50			
		MDA-MB-231	23.50 ± 0.90				
54l			IC$_{50}$ [µM]	Erlotinib		EGFR CDK2	8
		Cell line	Treatment	2.14 ± 0.30			
		MCF-7	3.40 ± 0.50	3.25 ± 0.50			
		MDA-MB-231	8.43 ± 0.60				
54n			IC$_{50}$ [µM]	Erlotinib		EGFR CDK2	8
		Cell line	Treatment	2.14 ± 0.30			
		MCF-7	3.90 ± 0.30	3.25 ± 0.50			
		MDA-MB-231	5.30 ± 0.40				

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
60h		**IC$_{50}$ [µM]**		Sorafenib	EGFR	94
		Cell line	Treatment	—		
		MDA-MB-231	16.80 ± 0.37			
		HepG2	17.00 ± 0.13	2.60 ± 0.00		
60i		**IC$_{50}$ [µM]**		Sorafenib	EGFR	94
		Cell line	Treatment	—		
		MDA-MB-231	18.50 ± 0.74			
		HepG2	13.50 ± 0.92	2.60 ± 0.00		
65		**IC$_{50}$ [µM]**		Nutlin-3	p53 expression and histone H4 acetylation; MDM2, and HDAC	16
		Cell line	Treatment	9.75 ± 2.97		
		MCF-7	1.37 ± 0.45	Hydroxamate 3.13 ± 0.78		
68b		**IC$_{50}$ [µg mL^{-1} and µM]**			Topo I Topo II	60
		Cell line	Treatment [µg mL^{-1}]	Topo I [µM]		
		HepG2	3.76 ± 0.40	0.119 ± 0.00		
		HCT-116	5.90 ± 3.40	0.042 ± 0.00		
		Caco-2	18.90 ± 2.40	Topo II [µM]		
		A-549	1.90 ± 0.10	4.469 ± 0.00		
		MCF7	NA	1.172 ± 0.00		

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
71f		Cell line *In vitro*	IC$_{50}$ [µM] Treatment 0.15 ± 0.02	Sulfamic acid 42.10 ± 7.80	h-ecto-5′-NT	95
74h		Cell line SCG7901	IC$_{50}$ [µM] Treatment 29.97 ± 0.00	— —	—	96
77e		Cell line Mcf7 HEK293 t	IC$_{50}$ [µM] Treatment 5.60 ± 0.60 6.10 ± 0.40	— — —	—	97
77f		Cell line A549	IC$_{50}$ [µM] Treatment 6.40 ± 0.40	*E. coli* MIC [µM] 1.30 ± 0.00	—	97

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity		Molecular target	Ref.
78e		IC$_{50}$ [μg mL^{-1} and μM]	S. aureus MIC$_{90}$ [μg mL^{-1}]	hmTrpRS and EoffTrpRS	98
		Cell line — Treatment [μM]	4.00 ± 0.00		
		OCI-Ly1 — 4.85 ± 0.51	—		
		SU-DHL4 — 2.97 ± 0.25	—		
		U2932 — 2.44 ± 0.18			
79l		IC$_{50}$ [μM]	5-Fluorouracil / Sunitinib	—	99
		Cell line — Treatment			
		MCF-7 — 3.60 ± 0.19	3.15 ± 0.44 / 3.97 ± 0.32		
		HCT116 — 3.24 ± 0.27	20.43 ± 1.99 / 9.67 ± 0.22		
		A431 — 2.43 ± 0.18	23.44 ± 2.09 / —		
79m		IC$_{50}$ [μM]	5-Fluorouracil / Sunitinib	EGFR and VEGFR-2	99
		Cell line — Treatment			
		PaCa-2 — 8.83 ± 0.51	— / 16.91 ± 0.95		

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity			Molecular target	Ref.
79k		IC$_{50}$ [µM]		Sunitinib	EGFR and VEGFR-2	99
		Cell line	Treatment	5-Fluorouracil		
		PaCa-2	8.83 ± 0.70	—	16.91 ± 0.95	
80		IC$_{50}$ [µM]		Cisplatin	—	100
		Cell line	Treatment			
		Jurkat	26.10 ± 0.00	12.00 ± 0.00		
		MCF-7	33.60 ± 0.00	11.40 ± 0.00		
		MDA-MB-231	35.50 ± 0.00	14.70 ± 0.00		
		HeLa	33.60 ± 0.00	7.70 ± 0.00		
		CEM	25.80 ± 0.00	4.40 ± 0.00		
		A-549	33.20 ± 0.00	12.20 ± 0.00		
81f		IC$_{50}$ [µM]		Nutlin-1	p53–MDM2 protein–protein interaction	101
		Cell line	Treatment			
		MCF7	3.05 ± 0.12	8.21 ± 0.25		
85		IC$_{50}$ [µM]			G1 phase arrest and cell fragmentation	102
		Cell line	Treatment			
		SU-DHL-4	1.14 ± 0.20	—		
		SUP–T1	1.62 ± 0.13	—		
		SUP–T1	0.61 ± 0.38	—		
		RS4; 11	0.32 ± 0.06	—		
		MIA-PaCa-2	1.90 ± 0.88	—		
		Capan-1	4.21 ± 0.95	—		

Table 1 (Contd.)

Cpd no.	Structure	Anti-cancer activity		Molecular target	Ref.
86		IC$_{50}$ [μM]		—	103
		Cell line	Treatment		
		HCT116	52.81 ± 0.00		
		PC3	74.40 ± 0.00		
		SNB19	101.00 ± 0.00		
		HL60	49.72 ± 0.00		
90p		IC$_{50}$ [μg mL^{-1} and μM]		G1/S phase cell cycle arrest	104
		Cell line	Treatment [μM]		
		A549	0.042 ± 0.00		
		S. aureus MIC [μg mL^{-1}]			
			25.00 ± 0.00		

antibacterial activity towards *S. aureus* (MIC = 25.00 μg mL^{-1}). Calf thymus DNA and *S. aureus* DNA put a low amount of biosensor to the probe by DNA damage test in terbium(III) chloride, while the concentration of the biosensor and the concentration of the results will show the damaging effect. Docking studies indicated intercalative binding within DNA strands. Compound **90p** could also inhibit tumor cell proliferation by arresting A549 cells at the G1/S phase of the cell cycle and promoting cell apoptosis by 33.65%, indicating that it might be a dual-purpose drug.[104]

Table 1 summarizes the biological findings of some recently synthesized halogenated spirooxindoles derivatives as anticancer agents, highlighting the effective molecular target. Halogenated spirooxindoles demonstrate significant anticancer activity through diverse mechanisms, including apoptosis induction, cell cycle arrest, and modulation of key oncogenic signaling pathways. Their structural rigidity and halogen substituents enhance binding affinity to molecular targets, improving therapeutic potential.

Conclusion

Halogenated spirooxindoles exhibit potent anticancer activity by precisely modulating molecular targets critical for cancer cell survival and proliferation. They have demonstrated promising *in vitro* and *in vivo* potency and selectivity across various cancer cell lines, with highlighted mechanisms of action. One of the promising molecular targets is protein kinases, which are involved in mechanisms of self-sufficiency in growth signals, evasion of growth suppressors, enabling replicative immortality, angiogenesis, and inducing invasion and metastasis. The synergistic effects of incorporating heterocyclic scaffolds and halogen bonding with the spiro scaffold's rigidity enhance their anticancer activity as effective and selective chemotherapeutics. Moreover, innovative synthetic strategies should be further explored to enhance anticancer efficacy while minimizing toxicity in cancer cells. Hopefully, novel, unique compounds prepared in this direction will be used in subsequent clinical studies to develop collaboration between basic and clinical cancer researchers.

Expert opinion

Halogenated spirooxindoles represent a significant advancement in targeted cancer therapy, particularly for p53-dependent cancers and those resistant to treatment. These compounds combine structural ingenuity with mechanistic precision, offering new opportunities for therapeutic development. The findings highlight the potential for medicinal chemists to optimize further halogen placement, scaffold rigidity, and hybrid designs, which could lead to the creation of novel, target-oriented chemotherapeutics. Halogen substitution may increase the ADME pharmacokinetics, binding affinities towards molecular targets, and enhance metabolic stability. Based on these promising results, halogenated spirooxindoles scaffolds are up-and-coming candidates for further development as anticancer agents. Therefore, continued research is

essential to investigate the effects of various substituents on the drug-like properties of these scaffolds, aiming to overcome existing challenges and optimize their potential as targeted chemotherapeutics.

Data availability

All data associated with this manuscript will be available upon reasonable request from the corresponding authors.

Conflicts of interest

The authors declare that they have no financial or personal interests.

Acknowledgements

References

1 L. Li, T. Shan, D. Zhang and F. Ma, Nowcasting and forecasting global aging and cancer burden: analysis of data from the GLOBOCAN and Global Burden of Disease Study, *J. Natl. Cancer Cent.*, 2024, **4**, 223–232, DOI: **10.1016/j.jncc.2024.05.002**.

2 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, *Ca-Cancer J. Clin.*, 2021, **71**, 209–249, DOI: **10.3322/caac.21660**.

3 G. R. Bhat, I. Sethi, H. Q. Sadida, B. Rah, R. Mir, N. Algehainy, I. A. Albalawi, T. Masoodi, G. K. Subbaraj, F. Jamal, M. Singh, R. Kumar, M. A. Macha, S. Uddin, A. S. A.-S. Akil, M. Haris and A. A. Bhat, Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance, *Cancer Metastasis Rev.*, 2024, **43**, 197–228, DOI: **10.1007/s10555-024-10172-z**.

4 R. Stojchevski, E. A. Sutanto, R. Sutanto, N. Hadzi-Petrushev, M. Mladenov, S. R. Singh, J. K. Sinha, S. Ghosh, B. Yarlagadda, K. K. Singh, P. Verma, S. Sengupta, R. Bhaskar and D. Avtanski, Translational Advances in Oncogene and Tumor-Suppressor Gene Research, *Cancers*, 2025, **17**, 1008, DOI: **10.3390/cancers17061008**.

5 Y.-Q. Liu, Y. Wu, B. Li, X. Tang and C. Chen, Recent advances in the organocatalytic synthesis of chiral C3-spiro-cyclopentaneoxindoles, *Org. Biomol. Chem.*, 2025, **23**, 757–773, DOI: **10.1039/D4OB01773K**.

6 P. K. Warghude, A. Bhowmick and R. G. Bhat, Stereoselective synthesis of spirooxindole scaffold, in *Spirooxindole*, Elsevier, 2024, pp. 283–308, DOI: **10.1016/B978-0-443-22324-2.00011-4**.

7 M. S. Islam, R. M. Al-Jassas, A. M. Al-Majid, M. Haukka, M. S. Nafie, M. M. Abu-Serie, M. Teleb, A. El-Yazbi, A. M. A. Alayyaf, A. Barakat and M. M. Shaaban, Exploiting spirooxindoles for dual DNA targeting/CDK2 inhibition and simultaneous mitigation of oxidative stress towards selective NSCLC therapy; synthesis, evaluation, and molecular modelling studies, *RSC Med. Chem.*, 2024, **15**, 2937–2958, DOI: **10.1039/D4MD00337C**.

8 M. S. Nafie, A. M. Al-Majid, M. Ali, A. A. Alayyaf, M. Haukka, S. Ashraf, Z. Ul-Haq, A. El-Faham and A. Barakat, Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells, *Front. Chem.*, 2024, **12**, 1364378, DOI: **10.3389/fchem.2024.1364378**.

9 M. S. Islam and V. P. Verma, Medicinal applications of spirooxindole and its derivatives, in *Spirooxindole*, Elsevier, 2024, pp. 537–585, DOI: **10.1016/B978-0-443-22324-2.00023-0**.

10 S. Nasri, M. Bayat and F. Mirzaei, Recent Strategies in the Synthesis of Spiroindole and Spirooxindole Scaffolds, *Top. Curr. Chem.*, 2021, **379**, 25, DOI: **10.1007/s41061-021-00337-7**.

11 D. M. Patel, P. J. Patel and H. M. Patel, Catalytic Stereoselective Multicomponent Reactions for the Synthesis of Spiro Derivatives: Recent Progress, *Eur. J. Org Chem.*, 2022, **2022**, e202201119, DOI: **10.1002/ejoc.202201119**.

12 N. K. Chouhan, M. N. Talati, M. Sharma and S. Pabbaraja, Anticancer effect of spirooxindole derivatives, in *Spirooxindole*, Elsevier, 2024, pp. 587–604, DOI: **10.1016/B978-0-443-22324-2.00024-2**.

13 L. R. Raposo, A. Silva, D. Silva, C. Roma-Rodrigues, M. Espadinha, P. V. Baptista, M. M. M. Santos and A. R. Fernandes, Exploiting the antiproliferative potential of spiropyrazoline oxindoles in a human ovarian cancer cell line, *Bioorg. Med. Chem.*, 2021, **30**, 115880, DOI: **10.1016/j.bmc.2020.115880**.

14 M. S. Islam, A. M. Al-Majid, E. N. Sholkamy, A. Barakat, M. Viale, P. Menichini, A. Speciale, F. Loiacono, M. Azam, V. P. Verma, S. Yousuf and M. Teleb, Optimized spirooxindole-pyrazole hybrids targeting the p53–MDM2 interplay induce apoptosis and synergize with doxorubicin in A549 cells, *Sci. Rep.*, 2023, **13**, 7441, DOI: **10.1038/s41598-023-31209-3**.

15 S. Chahal, J. Sindhu and P. Kumar, Medicinal application of spirooxindole and its derivatives: an introduction, in *Spirooxindole*, Elsevier, 2024, pp. 369–385, DOI: **10.1016/B978-0-443-22324-2.00014-X**.

16 Q. Zhao, S.-S. Xiong, C. Chen, H.-P. Zhu, X. Xie, C. Peng, G. He and B. Han, Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity, *Front. Oncol.*, 2022, **12**, 972372, DOI: **10.3389/fonc.2022.972372**.

17 M. S. Altowyan, S. M. Soliman, M. Haukka, N. H. Al-Shaalan, A. A. Alkharboush and A. Barakat, Synthesis, Characterization, and Cytotoxicity of New Spirooxindoles Engrafted Furan Structural Motif as a Potential Anticancer Agent, *ACS Omega*, 2022, **7**, 35743–35754, DOI: **10.1021/acsomega.2c03790**.

18 I. Shawish, A. M. Al-Majid and A. Barakat, Spirooxindole derivatives as an anticancer agent, in *Spirooxindole*, Elsevier, 2024, pp. 411–438, DOI: **10.1016/B978-0-443-22324-2.00016-3**.

19 S. Nishal, V. Jhawat, S. Gupta and P. Phaugat, Utilization of kinase inhibitors as novel therapeutic drug targets: areview, *Oncol. Res.*, 2022, **30**, 221–230, DOI: **10.32604/or.2022.027549**.

20 A. K. Rout, B. Dehury, S. N. Parida, S. S. Rout, R. Jena, N. Kaushik, N. K. Kaushik, S. K. Pradhan, C. R. Sahoo, A. K. Singh, M. Arya and B. K. Behera, A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target, *Int. J. Biol. Macromol.*, 2024, **270**, 132030, DOI: **10.1016/j.ijbiomac.2024.132030**.

21 E. V. Koroleva, A. L. Ermolinskaya, Z. V. Ignatovich, Y. V. Kornoushenko, A. V. Panibrat, V. I. Potkin and A. M. Andrianov, Design, *in silico* Evaluation, and Determination of Antitumor Activity of Potential Inhibitors Against Protein Kinases: Application to BCR-ABL Tyrosine Kinase, *Biochemistry*, 2024, **89**, 1094–1108, DOI: **10.1134/S0006297924060099**.

22 R. Moreddu, Nanotechnology and Cancer Bioelectricity: Bridging the Gap Between Biology and Translational Medicine, *Adv. Sci.*, 2024, **11**, 2304110, DOI: **10.1002/advs.202304110**.

23 J. Calder, A. Nagelberg, J. Luu, D. Lu and W. W. Lockwood, Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4, *Oncogenesis*, 2021, **10**, 27, DOI: **10.1038/s41389-021-00316-z**.

24 A. Javed, M. Yarmohammadi, K. S. Korkmaz and T. Rubio-Tomás, The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer, *Int. J. Mol. Sci.*, 2023, **24**, 2848, DOI: **10.3390/ijms24032848**.

25 W. Wei, M. Valerio, N. Ma, H. Kang, L. X. T. Nguyen, G. Marcucci and N. Vaidehi, Disordered C-Terminus Plays a Critical Role in the Activity of the Small GTPase Ran, *Biochemistry*, 2025, **64**, 1393–1404, DOI: **10.1021/acs.biochem.4c00484**.

26 P. Ghosh, T. Das, A. Chattopadhyay and P. Sahoo, Differential detection of aspartic acid in MCF-7 breast cancer cells, *Org. Biomol. Chem.*, 2023, **21**, 7018–7023, DOI: **10.1039/D3OB01072D**.

27 X. Cao, W. Wu, D. Wang, W. Sun and S. Lai, Glycogen synthase kinase GSK3α promotes tumorigenesis by activating HIF1/VEGFA signaling pathway in NSCLC tumor, *Cell Commun. Signaling*, 2022, **20**, 32, DOI: **10.1186/s12964-022-00825-3**.

28 S. Ali, M. Alam and Md. I. Hassan, Kinase inhibitors: an overview, in *Protein Kinase Inhib*, Elsevier, 2022, pp. 1–22, DOI: **10.1016/B978-0-323-91287-7.00026-0**.

29 J. M. Valverde, G. Dubra, M. Phillips, A. Haider, C. Elena-Real, A. Fournet, E. Alghoul, D. Chahar, N. Andrés-Sanchez, M. Paloni, P. Bernadó, G. Van Mierlo, M. Vermeulen, H. Van Den Toorn, A. J. R. Heck, A. Constantinou, A. Barducci, K. Ghosh, N. Sibille, P. Knipscheer, L. Krasinska, D. Fisher and M. Altelaar, A cyclin-dependent kinase-mediated phosphorylation switch of disordered protein condensation, *Nat. Commun.*, 2023, **14**, 6316, DOI: **10.1038/s41467-023-42049-0**.

30 Y. Wang, J. Zhang, C. Zheng, Z. Huang, W. Zhang, Y. Long, G. Gao, Y. Sun, W. W. Xu, B. Li and Q. He, C20orf24 promotes colorectal cancer progression by recruiting Rin1 to activate Rab5-mediated mitogen-activated protein kinase/extracellular signal-regulated kinase signalling, *Clin. Transl. Med.*, 2022, **12**, e796, DOI: **10.1002/ctm2.796**.

31 L. Miao, D. Pan, J. Shi, J. Du, P. Chen, J. Gao, Y. Yu, D.-Z. Shi and M. Guo, Role and Mechanism of PKC-δ for Cardiovascular Disease: Current Status and Perspective, *Front. Cardiovasc. Med.*, 2022, **9**, 816369, DOI: **10.3389/fcvm.2022.816369**.

32 M. M. Attwood, D. Fabbro, A. V. Sokolov, S. Knapp and H. B. Schiöth, Trends in kinase drug discovery: targets, indications and inhibitor design, *Nat. Rev. Drug Discovery*, 2021, **20**, 839–861, DOI: **10.1038/s41573-021-00252-y**.

33 X. Li, X. Li, F. Liu, S. Li and D. Shi, Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist, *J. Med. Chem.*, 2021, **64**, 10581–10605, DOI: **10.1021/acs.jmedchem.1c00683**.

34 D. Bora, A. Kaushal and N. Shankaraiah, Anticancer potential of spirocompounds in medicinal chemistry: a pentennial expedition, *Eur. J. Med. Chem.*, 2021, **215**, 113263, DOI: **10.1016/j.ejmech.2021.113263**.

35 P. Saraon, S. Pathmanathan, J. Snider, A. Lyakisheva, V. Wong and I. Stagljar, Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches, *Oncogene*, 2021, **40**, 4079–4093, DOI: **10.1038/s41388-021-01841-2**.

36 S. Waliany, J. J. Lin and J. F. Gainor, Evolution of first *versus* next-line targeted therapies for metastatic non-small cell lung cancer, *Trends Cancer*, 2025, **11**, 245–257, DOI: **10.1016/j.trecan.2025.01.005**.

37 R. Sharma, L. Yadav, A. A. Nasim, R. K. Yadav, R. H. Chen, N. Kumari, F. Ruiqi, A. Sharon, N. K. Sahu, S. K. Ippagunta, P. Coghi, V. K. W. Wong and S. Chaudhary, Chemo-/Regio-Selective Synthesis of Novel Functionalized Spiro [pyrrolidine-2,3'-oxindoles] under Microwave Irradiation and Their Anticancer Activity, *Molecules*, 2023, **28**, 6503, DOI: **10.3390/molecules28186503**.

38 D. H. Dawood, Therapeutic Insights of Indole Scaffold-Based Compounds as Protein Kinase Inhibitors,

ChemistrySelect, 2025, **10**, e202404767, DOI: [10.1002/slct.202404767](https://doi.org/10.1002/slct.202404767).

39 N. N. Chahat, Y. Murti, S. Yadav, P. Rawat, S. Dhiman and B. Kumar, Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy, *Mol. Divers.*, 2024, 1–26, DOI: [10.1007/s11030-024-10964-z](https://doi.org/10.1007/s11030-024-10964-z).

40 V. F. Batista, D. C. G. A. Pinto and A. M. S. Silva, Recent *in vivo* advances of spirocyclic scaffolds for drug discovery, *Expert Opin. Drug Discov.*, 2022, **17**, 603–618, DOI: [10.1080/17460441.2022.2055544](https://doi.org/10.1080/17460441.2022.2055544).

41 A. S. Girgis, Y. Zhao, A. Nkosi, N. S. M. Ismail, M. S. Bekheit, D. R. Aboshouk, M. N. Aziz, M. A. Youssef and S. S. Panda, The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53–MDM2 Modulation, *Pharmaceuticals*, 2025, **18**, 274, DOI: [10.3390/ph18020274](https://doi.org/10.3390/ph18020274).

42 G. Ranjan, S. Ranjan, P. Sunita and S. P. Pattanayak, Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology, *Naunyn. Schmiedebergs Arch. Pharmacol.*, 2024, **398**, 4705–4725, DOI: [10.1007/s00210-024-03661-z](https://doi.org/10.1007/s00210-024-03661-z).

43 M. K. Kumawat, N. Yadav and K. Kumar, Anticancer properties of spirooxindole derivatives, in *Spirooxindole*, Elsevier, 2024, pp. 333–367, DOI: [10.1016/B978-0-443-22324-2.00013-8](https://doi.org/10.1016/B978-0-443-22324-2.00013-8).

44 M. Panchal, S. Kaur, B. Pawar, T. Gupta, N. Vasdev, M. Tekade and R. K. Tekade, Importance of dose selection in toxicity studies, in *Public Health Toxicol. Issues Drug Res.*, Elsevier, 2024, vol. 2, pp. 87–119, DOI: [10.1016/B978-0-443-15842-1.00018-1](https://doi.org/10.1016/B978-0-443-15842-1.00018-1).

45 H. Guo, X. Xu, J. Zhang, Y. Du, X. Yang, Z. He, L. Zhao, T. Liang and L. Guo, The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies, *Pharmaceuticals*, 2024, **17**, 1048, DOI: [10.3390/ph17081048](https://doi.org/10.3390/ph17081048).

46 R. M. Al-Jassas, M. S. Islam, A. M. Al-Majid, M. S. Nafie, M. Haukka, A. F. M. M. Rahman, A. M. A. Alayyaf and A. Barakat, Synthesis and SARs study of novel spiro-oxindoles as potent antiproliferative agents with CDK-2 inhibitory activities, *Arch. Pharm.*, 2023, **356**, 2300185, DOI: [10.1002/ardp.202300185](https://doi.org/10.1002/ardp.202300185).

47 S. Kaur, J. Kaur, B. A. Zarger, N. Islam and N. Mir, Quantitative structure-activity relationship and ADME prediction studies on series of spirooxindoles derivatives for anti-cancer activity against colon cancer cell line HCT-116, *Heliyon*, 2024, **10**, e35897, DOI: [10.1016/j.heliyon.2024.e35897](https://doi.org/10.1016/j.heliyon.2024.e35897).

48 S. Sengupta, L. Maji, P. K. Das, G. Teli, M. Nag, N. Khan, M. Haque and G. S. P. Matada, Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship, *Mol. Divers.*, 2025, 1–31, DOI: [10.1007/s11030-024-11091-5](https://doi.org/10.1007/s11030-024-11091-5).

49 R. M. Al-Jassas, M. S. Islam, A. M. Al-Majid, M. Haukka, M. S. Nafie, M. M. Abu-Serie, M. Teleb, M. M. Shaaban, A. M. A. Alayyaf, L. R. Domingo, S. Ashraf, Z. Ul-Haq, Y. M. Abdel Aziz and A. Barakat, Marine-Inspired Spirooxindole PIM-1 Kinase Inhibitors Endowed with Concomitant TRKA/CDK2 Inhibition for Multifaceted Non-Small Cell Lung Cancer Apoptotic Induction, *ChemMedChem*, 2025, 2500028, DOI: [10.1002/cmdc.202500028](https://doi.org/10.1002/cmdc.202500028).

50 P. Chunarkar-Patil, M. Kaleem, R. Mishra, S. Ray, A. Ahmad, D. Verma, S. Bhayye, R. Dubey, H. Singh and S. Kumar, Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies, *Biomedicines*, 2024, **12**, 201, DOI: [10.3390/biomedicines12010201](https://doi.org/10.3390/biomedicines12010201).

51 BioRender, *BioRender.com*, Toronto, Canada: BioRender, 2025, Available from: https://biorender.com.

52 S. Shangary, K. Ding, S. Qiu, Z. Nikolovska-Coleska, J. A. Bauer, M. Liu, G. Wang, Y. Lu, D. McEachern, D. Bernard, C. R. Bradford, T. E. Carey and S. Wang, Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer, *Mol. Cancer Ther.*, 2008, **7**, 1533–1542, DOI: [10.1158/1535-7163.MCT-08-0140](https://doi.org/10.1158/1535-7163.MCT-08-0140).

53 Y. M. A. Aziz, G. Lotfy, M. M. Said, E. S. H. El Ashry, E. S. H. El Tamany, S. M. Soliman, M. M. Abu-Serie, M. Teleb, S. Yousuf, A. Dömling, L. R. Domingo and A. Barakat, Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53–MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation, *Front. Chem.*, 2021, **9**, 735236, DOI: [10.3389/fchem.2021.735236](https://doi.org/10.3389/fchem.2021.735236).

54 A. Barakat, S. Alshahrani, A. M. Al-Majid, A. S. Alamary, M. Haukka, M. M. Abu-Serie, L. R. Domingo, S. Ashraf, Z. Ul-Haq, M. S. Nafie and M. Teleb, New spiro-indeno [1,2-*b*]quinoxalines clubbed with benzimidazole scaffold as CDK2 inhibitors for halting non-small cell lung cancer; stereoselective synthesis, molecular dynamics and structural insights, *J. Enzyme Inhib. Med. Chem.*, 2023, **38**, 2281260, DOI: [10.1080/14756366.2023.2281260](https://doi.org/10.1080/14756366.2023.2281260).

55 J. Lee and J.-L. Roh, Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience, *Cancer Lett.*, 2023, **559**, 216119, DOI: [10.1016/j.canlet.2023.216119](https://doi.org/10.1016/j.canlet.2023.216119).

56 Q. Li, Z. Li, T. Luo and H. Shi, Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy, *Mol. Biomed.*, 2022, **3**, 47, DOI: [10.1186/s43556-022-00110-2](https://doi.org/10.1186/s43556-022-00110-2).

57 D. Fu, Z. Hu, X. Xu, X. Dai and Z. Liu, Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities, *Transl. Oncol.*, 2022, **26**, 101510, DOI: [10.1016/j.tranon.2022.101510](https://doi.org/10.1016/j.tranon.2022.101510).

58 S. M. Sagar, D. Yance and R. K. Wong, Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 1, *Curr. Oncol.*, 2006, **13**, 14–26, DOI: [10.3747/co.v13i1.77](https://doi.org/10.3747/co.v13i1.77).

59 J. M. Espejo-Román, B. Rubio-Ruiz, V. Cano-Cortés, O. Cruz-López, S. Gonzalez-Resines, C. Domene, A. Conejo-García and R. M. Sánchez-Martín, Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles, *Pharmaceutics*, 2022, **14**, 788, DOI: [10.3390/pharmaceutics14040788](https://doi.org/10.3390/pharmaceutics14040788).

60 S. El-Kalyoubi, M. M. Khalifa, M. T. Abo-Elfadl, A. A. El-Sayed, A. Elkamhawy, K. Lee and A. A. Al-Karmalawy, Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual Topo I/II inhibitors, DNA intercalators, and apoptotic inducers, *J. Enzyme Inhib. Med. Chem.*, 2023, **38**, 2242714, DOI: **10.1080/14756366.2023.2242714**.

61 S. S. Taylor, D. R. Knighton, J. Zheng, L. F. Ten Eyck and J. M. Sowadski, Structural framework for the protein kinase family, *Annu. Rev. Cell Biol.*, 1992, **8**, 429–462, DOI: **10.1146/annurev.cb.08.110192.002241**.

62 D. R. Knighton, J. H. Zheng, L. F. Ten Eyck, V. A. Ashford, N. H. Xuong, S. S. Taylor and J. M. Sowadski, Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase, *Science*, 1991, **253**, 407–414, DOI: **10.1126/science.1862342**.

63 J. Zheng, E. A. Trafny, D. R. Knighton, N. Xuong, S. S. Taylor, L. F. Ten Eyck and J. M. Sowadski, 2.2 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor, *Acta Crystallogr., Sect. D:Biol. Crystallogr.*, 1993, **49**, 362–365, DOI: **10.1107/S0907444993000423**.

64 N. M. Saleh, M. G. El-Gazzar, H. M. Aly and R. A. Othman, Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors, *Front. Chem.*, 2020, **7**, 917, DOI: **10.3389/fchem.2019.00917**.

65 O. P. J. van Linden, A. J. Kooistra, R. Leurs, I. J. P. de Esch and C. de Graaf, KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space, *J. Med. Chem.*, 2014, **57**, 249–277, DOI: **10.1021/jm400378w**.

66 S. Röhm, A. Krämer and S. Knapp, Function, Structure and Topology of Protein Kinases, in *Proteinkinase Inhibitors*, ed. S. Laufer, Springer International Publishing, Cham, 2021, pp. 1–24, doi: DOI: **10.1007/7355_2020_97**.

67 D. Fabbro, S. W. Cowan-Jacob and H. Moebitz, Ten things you should know about protein kinases: IUPHAR Review 14, *Br. J. Pharmacol.*, 2015, **172**, 2675–2700, DOI: **10.1111/bph.13096**.

68 S. Müller, A. Chaikuad, N. S. Gray and S. Knapp, The ins and outs of selective kinase inhibitor development, *Nat. Chem. Biol.*, 2015, **11**, 818–821, DOI: **10.1038/nchembio.1938**.

69 P. Cohen, D. Cross and P. A. Jänne, Kinase drug discovery 20 years after imatinib: progress and future directions, *Nat. Rev. Drug Discovery*, 2021, **20**, 551–569, DOI: **10.1038/s41573-021-00195-4**.

70 X.-J. Liu, H.-C. Zhao, S.-J. Hou, H.-J. Zhang, L. Cheng, S. Yuan, L.-R. Zhang, J. Song, S.-Y. Zhang and S.-W. Chen, Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy, *Bioorg. Chem.*, 2023, **133**, 106425, DOI: **10.1016/j.bioorg.2023.106425**.

71 P. J. Chaudhari, A. R. Nemade and A. A. Shirkhedkar, Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents, *RSC Adv.*, 2024, **14**, 33384–33417, DOI: **10.1039/D4RA05244G**.

72 M. J. McGregor, A Pharmacophore Map of Small Molecule Protein Kinase Inhibitors, *J. Chem. Inf. Model.*, 2007, **47**, 2374–2382, DOI: **10.1021/ci700244t**.

73 Q.-Q. Xie, H.-Z. Xie, J.-X. Ren, L.-L. Li and S.-Y. Yang, Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2, *J. Mol. Graph. Model.*, 2009, **27**, 751–758, DOI: **10.1016/j.jmgm.2008.11.008**.

74 M. W. Karaman, S. Herrgard, D. K. Treiber, P. Gallant, C. E. Atteridge, B. T. Campbell, K. W. Chan, P. Ciceri, M. I. Davis, P. T. Edeen, R. Faraoni, M. Floyd, J. P. Hunt, D. J. Lockhart, Z. V. Milanov, M. J. Morrison, G. Pallares, H. K. Patel, S. Pritchard, L. M. Wodicka and P. P. Zarrinkar, A quantitative analysis of kinase inhibitor selectivity, *Nat. Biotechnol.*, 2008, **26**, 127–132, DOI: **10.1038/nbt1358**.

75 L. T. Alexander, H. Möbitz, P. Drueckes, P. Savitsky, O. Fedorov, J. M. Elkins, C. M. Deane, S. W. Cowan-Jacob and S. Knapp, Type II Inhibitors Targeting CDK2, *ACS Chem. Biol.*, 2015, **10**, 2116–2125, DOI: **10.1021/acschembio.5b00398**.

76 Z. Zhao, H. Wu, L. Wang, Y. Liu, S. Knapp, Q. Liu and N. S. Gray, Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?, *ACS Chem. Biol.*, 2014, **9**, 1230–1241, DOI: **10.1021/cb500129t**.

77 T. T. Shivani and S. Chaudhary, Spirooxindole derivatives as an anticancer agents: Synthetic developments, structure–activity relationship, and biological applications, in *Spirooxindole*, Elsevier, 2024, pp. 387–409, **https://linkinghub.elsevier.com/retrieve/pii/B9780443223242000151**, accessed April 2, 2025.

78 H. A. Carlson, Protein flexibility and drug design: how to hit a moving target, *Curr. Opin. Chem. Biol.*, 2002, **6**, 447–452, DOI: **10.1016/S1367-5931(02)00341-1**.

79 G. Caron, V. Digiesi, S. Solaro and G. Ermondi, Flexibility in early drug discovery: focus on the beyond-Rule-of-5 chemical space, *Drug Discov. Today*, 2020, **25**, 621–627, DOI: **10.1016/j.drudis.2020.01.012**.

80 F. Lovering, J. Bikker and C. Humblet, Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success, *J. Med. Chem.*, 2009, **52**, 6752–6756, DOI: **10.1021/jm901241e**.

81 J. D. Amaral, D. Silva, C. M. P. Rodrigues, S. Solá and M. M. M. Santos, A Novel Small Molecule p53 Stabilizer for Brain Cell Differentiation, *Front. Chem.*, 2019, **7**, 15, DOI: **10.3389/fchem.2019.00015**.

82 B.-W. Pan, Y. Shi, S.-Z. Dong, J.-X. He, B.-S. Mu, W.-B. Wu, Y. Zhou, F. Zhou and J. Zhou, Highly stereoselective synthesis of spirocyclopropylthiooxindoles and biological evaluation, *Org. Chem. Front.*, 2022, **9**, 2640–2646, DOI: **10.1039/D2QO00300G**.

83 S.-J. Liu, Q. Zhao, C. Peng, Q. Mao, F. Wu, F.-H. Zhang, Q.-S. Feng, G. He and B. Han, Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro [pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation, *Eur. J. Med. Chem.*, 2021, **217**, 113359, DOI: **10.1016/j.ejmech.2021.113359**.

84 M. Kanchrana, B. S. Allaka, G. R. Krishna and S. Basavoju, An ultrasound assisted synthesis of spirooxindolo-1,2,4-oxadiazoles *via* [3 + 2] cycloaddition reaction and their anti-cancer activity, *Arkivoc 2023*, 2023, DOI: **10.24820/ark.5550190.p011.940**.

85 V. Yu. Korotaev, S. V. Barkovskii, I. B. Kutyashev, M. V. Ulitko, A. Yu. Barkov, N. S. Zimnitskiy, I. A. Kochnev and V. Ya. Sosnovskikh, Two approaches toward the regio- and stereoselective synthesis of *N*-unsubstituted 3-aryl-4-(trifluoromethyl)-4*H*-spiro-[chromeno[3,4-*c*]pyrrolidine-1,3′-oxindoles], *Chem. Heterocycl. Compd.*, 2021, **57**, 679–690, DOI: **10.1007/s10593-021-02967-7**.

86 A. M. Al-Majid, M. Ali, M. S. Islam, S. Alshahrani, A. S. Alamary, S. Yousuf, M. I. Choudhary and A. Barakat, Stereoselective Synthesis of the Di-Spirooxindole Analogs Based Oxindole and Cyclohexanone Moieties as Potential Anticancer Agents, *Molecules*, 2021, **26**, 6305, DOI: **10.3390/molecules26206305**.

87 A. Barakat, M. S. Islam, M. Ali, A. M. Al-Majid, S. Alshahrani, A. S. Alamary, S. Yousuf and M. I. Choudhary, Regio- and Stereoselective Synthesis of a New Series of Spirooxindole Pyrrolidine Grafted Thiochromene Scaffolds as Potential Anticancer Agents, *Symmetry*, 2021, **13**, 1426, DOI: **10.3390/sym13081426**.

88 S. Mayakrishnan, D. Kathirvelan, Y. Arun, K. Saranraj, C. Balachandran, S. Aoki, P. Yuvaraj and N. U. Maheswarai, Design and synthesis of spirooxindole–pyrrolidines embedded with indole and pyridine heterocycles by multicomponent reaction: anticancer and *in silico* studies, *New J. Chem.*, 2022, **46**, 10089–10106, DOI: **10.1039/D1NJ05839H**.

89 D. Rajaraman, L. A. Anthony, G. Sundararajan, M. Shanmugam and A. Arunkumar, Synthesis, NMR, anti-oxidant, anti-cancer activity, Molecular docking, DFT Calculations and *in silico* ADME analysis of 3′-benzoyl-4′-phenyl-5′-(piperazin-1-ylmethyl)spiro[indoline-3,2′-pyrrolidin]-2-one derivatives, *J. Mol. Struct.*, 2022, **1267**, 133551, DOI: **10.1016/j.molstruc.2022.133551**.

90 L. D. De Azevedo, D. I. Leite, A. P. De Oliveira, F. P. S. Junior, R. F. Dantas, M. M. Bastos, N. Boechat and L. C. F. Pimentel, Spirooxadiazoline-oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells, *Arch. Pharm.*, 2024, **357**, 2400029, DOI: **10.1002/ardp.202400029**.

91 S. Alshahrani, A. M. Al-Majid, M. Ali, A. S. Alamary, M. M. Abu-Serie, A. Dömling, M. Shafiq, Z. Ul-Haq and A. Barakat, Rational Design, Synthesis, Separation, and Characterization of New Spiroxindoles Combined with Benzimidazole Scaffold as an MDM2 Inhibitor, *Separations*, 2023, **10**, 225, DOI: **10.3390/separations10040225**.

92 R. S. Kumar, D. M. Al-thamili, A. I. Almansour, N. Arumugam and F. Mohammad, A One-Pot Three-Component Synthesis and Investigation of the *In Vitro* Mechanistic Anticancer Activity of Highly Functionalized Spirooxindole-Pyrrolidine Heterocyclic Hybrids, *Molecules*, 2020, **25**, 5581, DOI: **10.3390/molecules25235581**.

93 A. Barakat, M. Haukka, S. M. Soliman, M. Ali, A. M. Al-Majid, A. El-Faham and L. R. Domingo, Straightforward Regio- and Diastereoselective Synthesis, Molecular Structure, Intermolecular Interactions and Mechanistic Study of Spirooxindole-Engrafted Rhodanine Analogs, *Molecules*, 2021, **26**, 7276, DOI: **10.3390/molecules26237276**.

94 I. Shawish, S. Al Ayoubi, A. El-Faham, A. Aldalbahi, F. F. El-Senduny, F. A. Badria, M. Ríos-Gutiérrez, H. H. Hammud, S. Ashraf, Z. Ul-Haq and A. Barakat, Novel spirooxindole-triazole derivatives: unveiling [3+2] cycloaddition reactivity through molecular electron density theory and investigating their potential cytotoxicity against HepG2 and MDA-MB-231 cell lines, *Front. Chem.*, 2024, **12**, 1460384, DOI: **10.3389/fchem.2024.1460384**.

95 A. Ashraf, Z. Shafiq, M. S. Khan Jadoon, M. N. Tahir, J. Pelletier, J. Sevigny, M. Yaqub and J. Iqbal, Synthesis, Characterization, and *In Silico* Studies of Novel Spirooxindole Derivatives as Ecto-5′-Nucleotidase Inhibitors, *ACS Med. Chem. Lett.*, 2020, **11**, 2397–2405, DOI: **10.1021/acsmedchemlett.0c00343**.

96 F.-J. Zhou, B.-L. Zhu, Z.-H. Huang, N. Lin and Z.-W. Zhang, DBU-catalyzed diastereoselective 1,3-dipolar [3+2] cycloaddition of trifluoroethyl amine-derived isatin ketimines with chalcones: synthesis of 5′-CF$_3$ -substituted 3,2′-pyrrolidinyl spirooxindoles, *RSC Adv.*, 2024, **14**, 548–551, DOI: **10.1039/D3RA08127C**.

97 V. E. Filatov, D. A. Iuzabchuk, V. A. Tafeenko, Y. K. Grishin, V. A. Roznyatovsky, D. A. Lukianov, Y. A. Fedotova, M. A. Sukonnikov, D. A. Skvortsov, N. V. Zyk and E. K. Beloglazkina, Dispirooxindole-β-Lactams: Synthesis *via* Staudinger Ketene-Imine Cycloaddition and Biological Evaluation, *Int. J. Mol. Sci.*, 2022, **23**, 6666, DOI: **10.3390/ijms23126666**.

98 W. Ren, Q. Zhao, M. Yu, L. Guo, H. Chang, X. Jiang, Y. Luo, W. Huang and G. He, Design and synthesis of novel spirooxindole–indenoquinoxaline derivatives as novel tryptophanyl-tRNA synthetase inhibitors, *Mol. Divers.*, 2020, **24**, 1043–1063, DOI: **10.1007/s11030-019-10011-2**.

99 N. G. Fawazy, S. S. Panda, A. Mostafa, B. M. Kariuki, M. S. Bekheit, Y. Moatasim, O. Kutkat, W. Fayad, M. A. El-Manawaty, A. A. F. Soliman, R. A. El-Shiekh, A. M. Srour, R. F. Barghash and A. S. Girgis, Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties, *Sci. Rep.*, 2022, **12**, 13880, DOI: **10.1038/s41598-022-17883-9**.

100 M. Budovská, V. Tischlerová, J. Mojžiš, O. Kozlov and T. Gondová, An alternative approach to the synthesis of anticancer molecule spirobrassinin and its 2′-amino analogues, *Monatsh. Chem.*, 2020, **151**, 63–77, DOI: **10.1007/s00706-019-02528-x**.

101 D. M. Odeh, H. A. Allam, W. R. Mahmoud, M. M. Odeh, H. A. Abdel Aziz and E. R. Mohammed, One-pot three-component synthesis, *in vitro* anticancer activity and p53-MDM2 protein-protein interaction inhibition of novel

spiro-oxindoline-based pyrazolo[3,4-b]pyridines, Egypt, *J. Chem.*, 2024, **67**(3), 495–513, DOI: **10.21608/ejchem.2023.228742.8415**.

102 A. Eichhorst, M. Gallhof, A. Voss, A. Sekora, L. Eggers, L. T. Huyen, C. Junghanss, H. Murua Escobar and M. Brasholz, Spirooxindol-1,3-oxazine Alkaloids: Highly Potent and Selective Antitumor Agents Evolved from Iterative Structure Optimization, *ChemMedChem*, 2022, **17**, e202200162, DOI: **10.1002/cmdc.202200162**.

103 R. Westphal, E. Venturini Filho, L. B. Loureiro, C. F. Tormena, C. Pessoa, C. D. J. Guimarães, M. P. Manso, R. G. Fiorot, V. R. Campos, J. A. L. C. Resende, F. Medici and S. J. Greco, Green Synthesis of Spiro Compounds with Potential Anticancer Activity through Knoevenagel/Michael/Cyclization Multicomponent Domino Reactions Organocatalyzed by Ionic Liquid and Microwave-Assisted, *Molecules*, 2022, **27**, 8051, DOI: **10.3390/molecules27228051**.

104 M. S. Islam, A. Barakat, A. M. A. Alayyaf, M. Haukka, V. P. Verma, M. M. Abu-Serie, A. F. El-Yazbi, M. G. Shehat, M. Alseqely and M. Teleb, Synthesis of Marine-Inspired Multifaceted DNA Damaging Spirooxindoles Combating NSCLC and Associated Bacterial Infection, *ACS Med. Chem. Lett.*, 2025, 5c00014, DOI: **10.1021/acsmedchemlett.5c00014**.